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Silver nanoparticles (AgNPs) have received tremendous attention for their 
antimicrobial properties; however, many gaps in knowledge exist. To address these 
issues, three research objectives were examined. The first objective hypothesized AgNPs 
can be size selected and concentrated via tangential flow ultrafiltration. The second 
objective hypothesized a high-throughput method could be developed to screen 
nanoparticle antiviral-activity and cytotoxicity simultaneously. The third objective 
hypothesized AgNPs inhibit viruses by preventing viral entry.  
For objective one, a tangential flow ultrafiltration scheme was tested on AgNPs 
synthesized via the Creighton Colloid method. AgNPs were analyzed via transmission 
electron microscopy. In objective two, an HIV-1 vector was adapted to 96-well format 
and modified to utilize 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) for simultaneous cytotoxicity and antiviral measurement. The third objective was 
investigated using Vaccinia virus (VACV). AgNP effects on VACV entry were 
monitored through β-galactosidase reporter assay and confocal microscopy. Western 
blots detected AgNP/VACV interaction. Plaque assays monitored AgNP inhibition over 
the entire VACV replication cycle. MTT and trypan blue exclusion measured AgNP 
cytotoxicity. 
 iv 
In objective one, tangential flow ultrafiltration demonstrated size selection and 
concentration of AgNPs. Filtered AgNPs were uniform and unaggregated with average 
11 nm diameters. A high-throughput, standardized assay was developed in objective two. 
AgNPs had antiviral-activity at non-cytotoxic concentrations (IC50=16 μg mL-1). In the 
third objective, AgNPs prevented VACV entry in both cytoprotective and virucidal 
capacities at non-cytotoxic concentrations (IC50=48 μg mL-1). In the absence of 
macropinocytosis, AgNPs retained virucidal-activity but not cytoprotective effects. 
AgNPs bound to viral entry proteins. Plaque assays demonstrated that AgNPs inhibited 
the entire VACV replication cycle. Cytotoxicity assays demonstrated AgNPs were non-
cytotoxic at antiviral concentrations.  
Objective one’s size selection and concentration method permits accurate 
investigation into nanoparticle antimicrobial activity by eliminating size and reagent 
incompatibility problems inherent to AgNP synthesis. In objective two, the traditional 
viral titering assay was replaced with a standardized assay measuring simultaneously 
antiviral activity and cytotoxicity, permitting faster and cheaper antiviral screening of 
nanoparticles. In the third objective, AgNP-mediated antiviral-activity was pinpointed to 
viral entry. Multiple mechanisms of entry inhibition were observed. These data suggest 
that AgNPs can be potent and broad-spectrum antiviral agents and therapeutics. 
 v 
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Silver has been used for millennia as an antimicrobial agent. The Phoenicians 
used it to line pottery as it preserved potable goods stored within these containers (6). In 
Victorian England, silver salts were used in the treatment of sexually transmitted diseases 
and silver nitrate saw continued use as a disinfectant through the end of World War II 
(54). After the discovery of antibiotics, however, silver was relegated to very few uses as 
an antimicrobial agent. Antibiotics became preferable over silver salts because they were 
significantly less toxic to the host and more effective for systemic use (6). 
Silver Nanoparticles  
Due to the discovery of nanotechnology, silver is making a comeback in a variety 
of ways. Nanotechnology relies on the fabrication and manipulation of materials with at 
least one dimension between 1 and 100 nm. Having dimensions within this particular size 
window gives the material unique physical qualities. At this size, the material is too large 
to be considered on the atomic/ionic scale, yet far too small to be considered bulk 
material and, as a consequence, nanomaterials exhibit characteristics unlike their bulk or 
ionic counterparts. For example, nanomaterials exhibit less toxicity as compared to their 
ionic counterparts, yet they retain their antimicrobial activity. Compared to the bulk 
materials, nanoparticles exhibit greater antimicrobial effects.   
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 In the case of silver nanoparticles (AgNPs), the unique characteristics associated 
with the nanotechnology size window are reviving interests in developing silver as an 
antimicrobial agent, in addition to more non-traditional applications. Having one 
dimension between 1 and 100 nm means “naked” AgNPs, those without surface 
modifications or capping agents, have an extremely large surface area to volume ratio, 
thus resulting in a very low coordination number and very highly polarized surfaces (67). 
Naked AgNPs bind to biological material non-specifically through their inherent need for 
steric and electrostatic stabilization as a result of their highly polarized surfaces and 
empty S orbital at its zero valent state (8, 46). Covalent bonds are thus easily established 
with complexes containing nitrogen (amines/protein), phosphorus (phosphates/DNA) and 
sulfur (thiols/protein) being common electron donors (8). 
 The physical traits of AgNPs can be fine-tuned using different methods to 
fabricate AgNPs. Each method can impart different sizes, shapes, and surface elements, 
which change AgNP reactivity (14, 50). There are many methods of AgNP synthesis, but 
these methods can be broadly classified as wet or dry processes. One of the earliest 
examples of wet AgNP synthesis can be found in medieval cathedrals that contain stained 
glass. Although historic stained glass makers were unaware, their reduction of silver salts 
created AgNPs. Different reduction techniques created AgNPs of different sizes and thus 
different colors due to a property called Surface Plasmon Resonance (26). Modern wet 
synthesis techniques rely on the same basic properties with much greater precision. For 
example, the Creighton Colloid Synthesis method, in which sodium borohydride is used 
to reduce silver nitrate into AgNPs in a water matrix, is one of the most common methods 
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in use (30). Wet synthesis methods are commonly referred to as “bottom-up” synthesis 
methods because AgNPs are constructed atom by atom through a nucleation process.  
 
Figure 1. Preliminary characterization of different AgNPs. Each frame is a sample of many images 
taken to characterize the AgNPs. Bar = 100 nm. A) Commercially available bottom-up biosynthetic AgNPs 
with low concentration, high aggregation and high polydispersity. B) Ultraviolet radiation-based bottom-up 
AgNP synthesis with high polydispersity and very low concentration C) “50 nm” commercially available 
top-down synthesis AgNPs with high aggregation and possible stabilizing agent contamination D) “80 nm” 
commercially available top-down synthesis AgNPs with high polydispersity and amorphous shapes. E) “10 
nm” commercially available bottom-up synthesis AgNPs with observed aggregation and average 60 nm in 
diameter, not the advertised 10 nm. 
 
Dry synthesis methods of creating AgNPs are typically referred to as “top-down” 
methods because they involve breaking down bulk silver into AgNPs. One common 
method used today is laser ablation, where lasers are pulsed on a bulk piece of silver to 
break down the large starting material into AgNPs. With current manufacturing 
techniques, AgNPs synthesized in either a wet or dry synthesis demonstrate a high level 
of polydispersity (16). This polydispersity was documented in preliminary data acquired 
from transmission electron micrographs and subsequent particle analysis from a variety 
of AgNP synthesis methods (Figure 1). These commonly used AgNP synthesis methods 
were found to be too low in concentration, have high levels of polydispersity, have high 
levels of aggregation and/or have highly amorphous shapes as evidenced by the images 
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above (Figure 1). Each of these factors presents a problem in controlling effects of 
AgNPs on a biological system. The AgNPs sampled in the preliminary characterization 
were commercially available or synthesized “in-house” in efforts to find small, naked, 
uniform, and monodisperse AgNPs for studies involving their antiviral properties. None 
of the AgNPs in Figure 1 met these criteria. However, one commercially available AgNP 
preparation, NovaCentrix 25 nm AgNPs, was small, uniform and monodisperse, so it was 
chosen to carry out the research in Chapters III and IV while a technique to address the 
polydispersity present in other commercially available and “in-house” AgNP preparations 
is addressed in Chapter II. 
Currently, commercially available AgNPs are produced, through both wet and dry 
synthesis methods, and licensed for use in consumer products at an exponential rate. 
Applications utilizing AgNPs have multiplied over 1,000% since 2006, with AgNPs 
representing 313 of the 1317 licensed nanotechnology products (73). Most of the 
commercial applications for AgNPs are antimicrobial. For example, AgNPs are 
commercially available as preservatives (i.e. clothing and cosmetics), medical devices 
(i.e. coatings for catheters and wound dressings), and as water treatment agents with no 
defined mechanisms for their antimicrobial properties (21). 
Common to all AgNP synthesis methods is the problem of generating a uniform 
set of AgNPs, as shown in Figure 1 and discussed in the literature (16). Eliminating 
AgNP polydispersity has been shown to increase its antimicrobial properties, possibly as 
a consequence of increasing surface area and thus AgNP reactivity (3, 6). Current 
technologies using both wet and dry synthesis methods produce AgNPs with a broad size 
distribution, meaning the standard deviation of particle diameters is greater than 30% of 
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the average diameter measurement (14). To correct for this problem, many of the 
techniques used to produce AgNPs have been adapted to use additional materials during 
AgNP synthesis that function to restrict particle size to a narrow distribution in the final 
product. Examples of common additional agents, referred to as capping agents or 
stabilizers, added to naked AgNPs, are polyvinylpyrrolidone, citrate and polyethylene 
glycol. These agents have been proven biologically compatible; however, they posses 
their own antimicrobial properties, which would make the identification of inherent 
AgNP antiviral activity difficult (6, 39). These capping agents may even enhance toxicity 
to host cells by allowing greater distribution of AgNPs in tissues, extending their half life 
within the host cell or organism, or enhancing AgNP surface charges and reactivity to 
augment cytotoxicity over “naked,” un-capped AgNPs (1, 22). Other organic and 
chemically aggressive reagents currently used to control AgNP size, shape and dispersity 
are incompatible with biological systems precluding their use in the manufacture of 
antimicrobial agents (14, 50, 59, 60). To overcome the limitations of current AgNP 
synthesis techniques and further investigate AgNPs as antimicrobials, a method of 
purifying, size selecting, and concentrating naked nanoparticles is needed. 
 Silver Nanoparticles as Antiviral Agents 
 Very few drugs are approved as therapies for viral infection. Most of the approved 
drugs are specifically designed for one species of virus and would not work in a broad-
spectrum capacity. The most common examples of these types of drugs are the 
nucleoside analogs specific for Herpes virus infection and the neuraminidase inhibitors 
available for Influenza virus infection. While extremely effective, these drugs require the 
accurate identification of invading virus before prescriptions can be filled (45). Also 
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associated with these drugs is an emerging pattern of antiviral drug resistance due to the 
specificity in their mechanisms of action and natural selection for resistant strains (9, 56). 
The pattern of antiviral drug resistance is most exemplified by chronic infections with 
Human immunodeficiency virus 1 (HIV-1) and Hepatitis viruses. Current HIV-1 therapy, 
highly active anti-retroviral therapy, utilizes multiple drugs to specifically inhibit 
different proteins in viral replication such as the viral protease, reverse transcriptase and 
integrase. Even with multiple targets, resistant viral strains still emerge due to the high 
mutation rate of HIV-1 and the resultant mutants resistant to the specific inhibitors (9). 
For Hepatitis virus infection, treatments were designed using broad-spectrum, non-
specific inhibitors in hopes to waylay the development of drug resistance. Interferon α, 
an innate immunity protein responsible for generating antiviral responses in the body, and 
Ribavirin, a suspected nucleoside analog, are used in conjunction for the treatment of 
Hepatitis C virus infection (10, 13). These drugs are broad-spectrum antivirals but they 
are not without their shortcomings. Interferon α therapy is associated with flu-like 
symptoms, hepatotoxicity, depression, and overtime interferon resistance (13). Ribavirin 
is a purine analog, not found in nature, originally synthesized in 1970. A wide range of 
RNA and DNA viruses have demonstrated susceptibility to Ribavirin despite the 
unknown mechanism(s) of activity. Ribavirin therapy has shown less instances of 
resistance but it is also associated with high levels hemotoxocity, differences in viral 
species/strain tolerance levels, and is a documented tetratogen (10). A new, broad 
spectrum antiviral therapy, with no existing viral resistance is desperately needed (56). 
The best defense available to viral infection was, and still is, vaccination. 
However, vaccination may not be possible in cases of emerging infectious diseases, the 
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deployment of biological weapons, diseases that have proven difficult for development of 
vaccines, and the continued antigenic drift that can render current vaccines useless (9). 
Vast amounts of time and resources are required to identify viruses and generate vaccines 
with the best protection generated from pre-exposure prophylaxis (36). When a vaccine is 
unavailable one could rely on the use of the previously mentioned drugs; however, due to 
their specificity or associated toxicity, an accurate diagnosis must be made which takes 
time. A true broad-spectrum antiviral agent, effective against many viral species/strains, 
that does not require a diagnosis is greatly needed in the antiviral agent arsenal.   
The antimicrobial properties of AgNPs have been evaluated for a wide range of 
bacteria, viruses, and fungi (6, 53, 55). Various mechanisms for the antimicrobial 
properties of AgNPs have been proposed; most of these mechanisms are based on the 
suggested mechanisms for silver ion toxicity due to the same elemental composition of 
AgNPs and Ag+. These proposed mechanisms include reactive oxygen species (ROS) 
production, disruption of membrane potential, depletion of intracellular ATP, inactivation 
of proteins, DNA damage and the production of silver ions from the AgNP surface, 
which would then mediate the previously listed mechanisms (53, 55). However, each of 
these mechanisms has been suggested based on evidence from AgNPs with different 
characteristics such as size, shape, capping agent, and level of dispersity. No solidly 
defined mechanism for AgNP antimicrobial activity is currently available. 
This manuscript will focus on the antiviral aspects of AgNPs. Very little is known 
concerning the mechanisms by which AgNPs exert their antiviral properties. However, 
AgNPs have demonstrated antiviral activity against a number of viruses for both 
prokaryotic and eukaryotic organisms, making them a true broad-spectrum antiviral 
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agent. Inhibition of infection by AgNPs has been well documented for the UZ1, MS2 and 
M13 bacteriophages (4, 21, 34, 68). The eukaryotic pathogens HIV-1, Herpes simplex 
virus 1 (HSV-1), Herpes simplex virus 2 (HSV-2), Monkeypox virus (MPV), Hepatitis B 
virus (HBV) and Tacaribe virus (TCRV) have also demonstrated a susceptibility to 
AgNPs (4, 23, 32, 35, 49, 57, 58). Such broad ranges of susceptible viral species indicate 
that AgNPs are an ideal candidate to be developed as a broad-spectrum antiviral agent. 
In each case of viral inhibition there has been documentation of a dependence on 
AgNP size for antiviral activity. One such study demonstrated that only small AgNPs, of 
25 nm or less, were able to bind to the external membrane glycoprotein 120 knobs of 
HIV-1, which are responsible for receptor binding (23). The mechanism for this 
inhibition was proposed to be prevention of HIV-1 entry into the host cell based on 
observations that AgNPs prevented syncytia formation, a late stage indicator of HIV-1 
infection.  
Additional studies indicated that early infection might be the general time frame 
where AgNPs exert their antiviral activity which then impacts the rest of the viral 
replication cycle. AgNPs are able to prevent HIV-1 CD4/gp120 mediated cell fusion, 
indicating that AgNPs have the potential to inhibit virus entry; however, this study was 
performed in a HIV-1 free manner where CD4 and gp120 were over-expressed in target 
cells (32). HBV virus-like particles with bound AgNPs were also directly observed via 
transmission electron microscopy (35). Furthermore, AgNPs inhibited MPV and HSV-2 
infection as determined by plaque assay, a measurement that includes the entire viral 
replication cycle (49, 57). TCRV inhibition by AgNPs was observed via quantification of 
progeny genomes, an endpoint that encompasses the entire replication cycle of the virus 
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(58). Generally, smaller AgNPs, less than or equal to 25 nm, have demonstrated the 
greatest antiviral potential. Furthermore, each study suggested that early steps in the 
infection process are the likely general time point for AgNP-mediated antiviral activity. 
However, a precise mechanism of AgNP antiviral activity and precise stage of infection 
at which AgNPs exert antiviral activity have yet to be determined. If a mechanism(s) 
could be identified, further studies are possible regarding the antiviral development of 
AgNPs to fill the vital niche of a broad-spectrum antiviral agent. 
Mechanisms suggested for the antibacterial effects of AgNPs, such as ROS 
production, disruption of membrane potential, depletion of ATP and DNA damage, are 
downstream, long-term events that require an active metabolism that is not present in 
viruses. Silver ion leaching, the suggested mechanism by which the antibacterial 
activities occur, as a method of antiviral activity is unlikely as all leached ions would 
quickly complex with free chlorine ions in the cellular growth medium (17). Furthermore, 
Navarro et al. demonstrated that less than 1% of the silver in culture media containing 
AgNPs was in the ionic form after 8 days of AgNP exposure to a synthetic growth 
medium (41). While the previously mentioned mechanisms might affect host cells, these 
mechanisms are unlikely to be the cause of early viral infection inhibition due to the long 
exposure times required for these events. The most likely mechanism of antiviral activity, 
as suggested by the literature, is AgNPs binding to viral or host proteins and inactivating 
or decreasing their function at an early stage of infection.  
 With no specific time point identified as the target of AgNP-mediated antiviral 
activity, more precise and mechanistic studies of where and when AgNPs exert their 
antiviral activity are necessary. Additionally, new methods of examining AgNP-mediated 
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antiviral activity are in great need. Traditional antiviral testing methods such as plaque 
assays are subjective and costly due to the personnel and resources required. High-
throughput methods of detecting antiviral activity are also currently unable to distinguish 
between antiviral effects, cytotoxicity and inherent characteristics of AgNPs that may 
interfere with automation, such as surface plasmon resonances. Furthermore, these assays 
measure the entire course of viral infection so, if viral inhibition is recorded, there is little 
to no indication of how or when this inhibition might occur. 
 It is critical that new methods of producing and screening for antiviral activity of 
AgNPs be developed because AgNPs could have significant benefits over traditional 
antiviral agents. Because they are a metal they are resistant to extremes in temperature, 
unlike current antiviral agents and vaccines that require temperature regulation. This 
resiliency could also favor multiple methods of deployment, oral, inhalation, topical 
application and even possible injection. Since AgNPs’ proposed mechanism of antiviral 
activity is non-specific binding of biological molecules such as proteins, theoretically all 
known viral species would be susceptible since no known viral species is devoid of 
protein. While cellular proteins would also be impacted by AgNP binding, viruses could 
be uniquely susceptible to AgNP binding as they are unable to regenerate damaged 
proteins. The broad-spectrum activity of AgNPs would be useful for those situations were 
a treatment is needed prior to a diagnosis being made or in the absence of a working 
vaccine (9, 45). Traditional antivirals are demonstrating a fast emerging resistance, but 
since the proposed mechanism of AgNP antiviral activity is interaction with viral 
proteins, the probability of AgNP resistant viruses developing is low. 
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Silver Nanoparticle Cytotoxicity 
 In addition to the studies performed concerning antimicrobial activities of AgNPs, 
there is a growing body of research concerning their toxicity. Drawing specific 
conclusions from sources of literature concerning the general toxicity of AgNPs is 
difficult. Most studies utilize different sets of AgNPs with differences in size, shape, 
surface elements, distribution, and synthesis methods with poor particle characterization 
being a common issue. Differences in AgNP characteristics can cause markedly different 
reactive properties, especially in biological systems (40). In vitro cytotoxicity values for 
lethal dose 50% (LD50) in the literature range from 0.7 μg mL-1 to greater than 449 μg 
mL-1 with no LD50 values reached for in vivo studies (2, 31). These differences in the 
literature make the question of AgNP toxicity a difficult one to answer. A precise 
mechanism responsible for AgNP cytotoxic observations has not been proposed due to 
the lack of standard assays to accurately assess AgNP cytotoxicity and the lack of 
experimental controls that exclude possible contamination of AgNPs with the toxic 
chemicals used in their synthesis. Gaps in knowledge surrounding AgNP cytotoxicity are 
critical questions to address in the development of a broad-spectrum antiviral agent as 
they could potentially mask antiviral activity. 
Viral Vectors 
Viral vectors offer a unique platform upon which the antiviral activity of a 
material such as AgNPs might be examined. At their most basic level, viral vectors are 
tools for delivering genetic information into a host cell (24). What makes a viral vector 
different from a wild type virus is its genetic modification to render the virus replication 
deficient. This modification allows the virus to successfully infect a cell and deliver its 
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genetic payload, but prevents the virus from reproducing. This functionality could be 
adapted to test AgNPs and other nanomaterials for antiviral activity in high-throughput 
fashion by determining whether or not AgNPs prevent the previously mentioned genetic 
transfer, a measure of infection. 
The most popular viral vector system is based on the Lentivirus HIV-1 (24). HIV-
1 is a single stranded RNA virus of the family Retroviridae. Typical wild type infection 
with HIV-1 follows classical type I viral entry kinetics via specific virus/host interaction 
at the plasma membrane of the cell, followed by the reverse transcription of viral RNA 
and subsequent integration of proviral DNA (18). At this point the transcription of 
proviral genes may then facilitate the production of progeny virions. In the viral vector 
system, the genes required to produce progeny virions are not incorporated into the viral 
genome, instead they are replaced with the genes to be delivered to the host cell. 
Additionally, the specific HIV-1/host cell interaction required for wild type viral 
infection is replaced by a viral receptor of choice. This envelope protein replacement 
permits the production of viral vector particles that can simulate the infection of many 
different viral species simply by utilizing their envelope proteins responsible for entry. 
For example, a common envelope protein replacement for an HIV-1 vector is the switch 
from HIV-1 wild type gp120 envelope protein to the Vesicular stomatitis virus G 
glycoprotein (28). This swap confers broad tropism onto the vector virions instead of the 
gp120/CD4 specific reaction of wild type HIV-1, which limits tropism to only those cells 
expressing CD4 and appropriate co-receptors. The ability to simulate many different viral 
species by interchanging the viral entry proteins would be a standardizing measure that 




As a result of the bioterrorism attacks in 2001, the Department of Health and 
Human Services has named broad-spectrum antimicrobial discovery and development a 
top priority (66). The National Institute of Allergy and Infectious Disease also lists 
discovery and development of therapeutics for Category A pathogens a top priority. 
Variola major, an Orthopoxvirus and the causative agent of smallpox, is a Category A 
pathogen and a growing concern for use in a potential biological weapon due to 
decreased population immunity as a result of the cessation of vaccination.  
 Study of Variola major virus is highly restricted to only one location within the 
United States. However, an accurate analog for the study of Variola major is available in 
the form of the virus used as the vaccine for smallpox, Vaccinia virus. Vaccinia virus 
(VACV), also an Orthopoxvirus, is similar enough to Variola major that exposure to 
VACV offers immunity to Variola major. Due to their similarities, VACV has become 
the gold standard for research on Orthopoxviruses and also for this reason, would make a 
great system for the development of a rapid-response antiviral agent in the event of the 
re-emergence of smallpox or the emerging disease monkeypox.  
VACV is a double stranded DNA virus of about 200 kb. VACV replicates solely 
in the host cell cytoplasm. The large genome encodes almost all of the structural proteins 
and enzymes required to complete its replication process (19).  
 The infection process typically begins with VACV adsorption to the membrane of 
a permissible host cell (Figure 2). This binding to the cell surface is accomplished 
through VACV membrane proteins A27 and H3, D8, L1 and A26, which bind heparan 
sulphate, chondroitin sulphate, and laminin respectively (15, 25, 27, 33, 47, 70). At this 
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stage in the infection process the virion is bound to the cell surface but entry has not yet 
occurred.  
There are discrepancies in reports on the process of adsorption. Observations exist 
for strain differences at the adsorption step prior to VACV entry into the host cell. 
Certain strains, IHD-J, Elstree, and Copenhagen, show a high level of dependence on the 
presence of glycosainoglycans (GAGs) such as heparan sulphate, while other strains, 
such as Western Reserve (WR) and Wyeth, show tolerance to the absence or interference 
of cellular binding factors (5). Non-GAG dependent adsorption may occur through 
laminin or could be completely bypassed by virions contacting the vesicle membrane as a 
result of a macropinocytotic mechanism. This variation in viral adsorption makes VACV 






Figure 2. Ouline of VACV Infection. VACV once absorbed to its host cell can proceed via two routes to 
gain access to the host cell cytoplasm. As indicated above these methods are either direct fusion to the 
plasma membrane or macropinocytotic uptake, followed by fusion with the macropinocytotic vesicle. 
 
 VACV entry is dependent on a set of entry fusion complex proteins. Entry of 
VACV via the entry fusion complex (EFC) has been demonstrated at both neutral and 
low pH corresponding to direct fusion and macropinocytosis-dependent fusion 
respectively. These differences demonstrate that VACV is capable of two distinct entry 
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methods (7, 52, 69). Identified as a complex of proteins, the EFC is composed of A16, 
A21, A28, F9, G3, G9, H2, I2, J5, L1, L5, and O3 with nine out of twelve of these 
proteins considered integral members of the EFC as their disruption or removal 
destabilizes the complex (7, 11, 29, 42, 43, 43, 44, 51, 62, 63, 65, 72). The EFC proteins 
are highly conserved among all poxviruses and mutation of any of these components 
yields non-infectious virions (52). The stoichiometry of the complex and its precise 
mechanism of action have yet to be classified or determined (71). The EFC is theorized to 
be the facilitator of virion membrane fusion with the host cell membranes for both 
methods of VACV entry.  
 Entry into the host cell is broadly characterized as the delivery of the virion core 
to the cytoplasm, regardless of how the virions are adsorbed or gain access to the host 
cell cytoplasm. The viral core comes equipped with all the enzymes necessary to begin 
early transcription (48). Once the viral core has entered the cytoplasm it immediately 
begins to transcribe early genes (12). This process has been well documented and is 
easily assayed within the first 6 hours of VACV infection via β-galactosidase expression 
driven by a constitutive early/late promoter (29, 70).  
One mode of VACV entry is acid mediated and dependent on viral uptake into a 
macropinocytotic vesicle. VACV entry through macropinocytosis has been proposed 
based on evidence that low pH treatment of bound VACV increased entry ten-fold (64). 
Electron microscopy has also demonstrated VACV occupying macropinocytotic vesicles 
(20). Furthermore, inhibitors of acidification drastically reduce VACV entry (61, 64). 
Also, an 83% reduction in viral entry has been observed upon dominant negative 
expression of Pak1, a vital component of macropinocytosis. Without this component 
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there is little to no macropinocytotic uptake of virions, and the virus is not exposed to the 
acidic environment of the macropinosome. The decreased infectivity as a result of Pak1 
inactivation was recovered by brief acid-buffer treatment of virions attached to the 
surface of the cell, supporting Pak1’s role in mediating macropinocytosis and VACV’s 
macropinocytosis-dependent fusion upon exposure to the low pH environment of the 
macropinosome (37).  
 The other mode of VACV entry is direct fusion with the plasma membrane. This 
method of entry has been shown experimentally by VACV indifference to a variety of 
endosomal acidification inhibitors (64). Furthermore, direct observation via electron 
microscopy has shown that strains WR and Modified Ankara Virus fuse directly with the 
plasma membrane (15). Also, viral membrane proteins examined via transmission 
electron microscopy after immuno-labeling were found to be part of the plasma 
membrane immediately after core delivery (47). This finding is indicative of the viral 
membrane, and its incorporated proteins, fusing with the plasma membrane without 
macropinocytotic uptake. 
Based on the evidence, it seems the preferred entry method, like adsorption 
method, varies from strain to strain and that each strain is capable of utilizing both 
methods of entry to a certain extent. Viral strains that are highly dependent on GAGs for 
adsorption could compensate by using Laminin for adsorption or instead depend more on 
direct fusion with the plasma membrane. Generally, VACV strains that are tolerant to a 
lack of cellular attachment factors generally depend more on macropinocytotic uptake. 
However, WR, a popular research strain, has been observed directly fusing with the 
plasma membrane, while other reports claim this strain is dependent on macropinocytotic 
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uptake for subsequent entry into the cell cytoplasm (15, 38, 64). This discrepancy could 
be the result of cell type dependent entry but suggests that this viral strain uses both entry 
methods to gain access to the host cell cytoplasm. The ability to enter cells in a variety of 
methods makes VACV an ideal candidate for the development of a broad-spectrum 
antiviral agent. 
Research Objectives and Rationale 
 In order to address the previously mentioned gaps in knowledge surrounding the 
biological applications of AgNPs, three research objectives were identified. Each 
objective was designed around a central hypothesis. Furthermore, each objective’s 
hypothesis was investigated via a set of specific aims designed to fully explore the gaps 
in knowledge of each respective field. 
The first objective hypothesized that highly concentrated, highly homogenous, 
non-aggregated AgNPs can be size selected and concentrated via tangential flow 
ultrafiltration. This hypothesis manifested from the lack of accurate methods capable of 
producing AgNPs free of contaminants from their synthesis, with limited polydispersity 
and without the use of capping or stabilizing agents. To test this hypothesis specific 
research aims were established.  
The first aim sought to develop a tangential flow ultrafiltration scheme capable of 
size selecting and concentrating AgNPs synthesized via Creighton method. This aim 
addressed the issues surrounding the production of AgNPs with limited polydispersity in 
the absence of capping or stabilizing agents that may interfere with the use of AgNPs as 
antimicrobial agents. The second aim examined the relative size selection and 
concentration effectiveness between the newly developed tangential flow ultrafiltration 
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scheme and the commonly used ultracentrifugation method for the size selection and 
concentration of AgNPs.  
 The development of more precise and higher-throughput methods for examining 
the antiviral activity of AgNPs was the focus of the second research objective. Because 
traditional plaque assays are subjective and require large amounts of time and money, a 
quicker high-throughput format for screening antiviral activity is desirable. Additionally, 
current techniques rely on performing cytotoxicity assays separately from the antiviral 
testing. This separation can result in the masking of antiviral activity by cytotoxicity. 
This objective also addressed the need for standardization of antiviral testing between 
viral species, since current methods require separate assays for different viral species.  
To address the issues surrounding the second objective, three research aims were 
developed. The first aim sought to adapt a large scale screening technique for HIV-1 
mutation rate, utilizing a viral vector system, to a small-scale, high-throughput format 
designed to assess viral titer. Aim two of this objective characterized the ability the novel 
assay format to accurately assess viral titer compared to the original colony forming unit 
assay. The third aim of the second objective was to determine the assay’s ability to 
simultaneously chart antiviral activity and cytotoxicity. 
 The third objective hypothesized that AgNP mediated antiviral activity was the 
result of AgNPs preventing viral entry. This objective would pinpoint the stage of viral 
infection at which AgNP antiviral activity occurs and illuminate possible mechanisms 
behind this inhibition, a vital gap in knowledge concerning AgNP antiviral activity. 
VACV was chosen as the viral system to examine AgNP-mediated antiviral activity and 
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its possible mechanisms due to the call to research by various governmental agencies and 
the growing concern for the use of Variola major as a potential bioweapon.  
The third objective’s hypothesis would be investigated through three specific 
aims. The first aim sought to investigate the effects of AgNPs on the adsorption of 
VACV to host cells. Determination of AgNP effects on overall VACV entry was 
addressed in the second aim of this objective. Finally, the third aim examined the effects 
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A proposed tangential flow ultrafiltration method was compared to the widely-
used ultracentrifugation method for efficiency and efficacy in concentrating, size 
selecting and minimizing the aggregation state of a silver nanoparticle (AgNP) colloid 
while probing the AgNPs’ SERS-based sensing capabilities. The ultrafiltration method 
proved to be more efficient, more effective and was found to tremendously boost the 
SERS-based sensing capabilities of these AgNPs through the increased number of 
homogenous SERS hot spots available for a bio-target molecule within a minimal focal 
volume. Future research studies and applications that address the physiochemical 
properties or biological impact of AgNPs would greatly benefit from ultrafiltration for its 
ability to generate monodisperse colloidal nanoparticles, to eliminate excess toxic 
chemicals from nanoparticle synthesis and to generate minimum levels of aggregation 




Silver nanoparticle (AgNP) preparation and manipulation is an extremely active 
research area due to the numerous applications of these nanomaterials to catalysis, 
photonics, electronics, biosensing, drug delivery, pharmaceuticals, etc.1 One of the most 
exciting and demanding applications of AgNPs is their surface-enhanced Raman 
spectroscopy (SERS)-based biosensing capability. SERS is a powerful analytical 
technique used to detect specific molecular vibration modes, which has experienced an 
explosive interest due to its strong molecular specificity and its extremely low detection 
limits, down to the single-molecule level.2a,b Theory predicts2c,d and experiments 
confirm2a,b, 1c that exceptionally large increases in Raman cross-section, or signals 
attained through Raman spectroscopy, are associated with molecules located in the nano-
sized interstitial sites of interacting colloidal AgNPs (i.e. hot spots). 
Significant challenges remain for the preparation and isolation of colloidal AgNPs 
with controlled polydispersity, toxicity and aggregation. Limiting AgNP polydispersity 
(i.e., narrow size and shape distribution)3a improves the optical/electronic properties,2c,d, 3a 
SERS enhancement factors, or increases in Raman signals corresponding to the presence 
of an enhancement material,2c,d and antimicrobial properties.1e 3f Reducing AgNP toxicity 
by eliminating chemically aggressive reagents or organic solvents3a,c significantly lowers 
the impact to biological systems, while facilitating the identification of novel activities 
and mechanisms.1e, 3c-e Minimizing AgNP aggregation at higher concentrations1c, 3a,c 
allows the assessment of SERS nanostructure-function relationship,2c,d improves the 
cellular uptake of AgNPs1c, 3d-f and maintains the number of potentially active catalytic 
sites.1a Additionally, use of methods such as centrifugation,4a size exclusion 
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chromatography,4a,b gel electrophoresis,4c diafiltration,4d size-dependent solubility4e and 
fractional crystallization4f have been reported for the size-based separation and/or 
concentration of NPs. These approaches may lead to issues with aggregation,4a 
instability,4a cost,4b, 4e undesired coatings,4c 4f and less effective protocols for NPs of 
smaller size.4f As a result, these methods are time intensive, expensive, toxic or 
inefficient.4 These limitations were overcome in this study by using a tangential flow 
ultrafiltration method, commonly used for weight-based separation of proteins, but not 
yet tested on silver or polydisperse colloids.4d This method relies on passing a fluid 
through a hollow fiber with specific pore sizes, allowing the solvent to pass through the 
pores and retaining solutes possessing sizes larger than the pore size within the hollow 
fiber. Tangential flow ultrafiltration is a single pass procedure to size select and to 
concentrate a target species using a series of membrane-modules with pores ranging from 
1 nm to 100 μm. The proposed method was compared to the widely-used 
ultracentrifugation method for efficiency and efficacy in concentrating, size selecting and 
minimizing the aggregation state of an AgNP colloid while probing the AgNPs’ SERS-
based sensing capabilities. 
RESULTS AND DISCUSSION 
Colloidal AgNPs were synthesized according to a well-known, inexpensive 
Creighton method by the simple reduction of silver nitrate with sodium borohydride. 
Once synthesized, the 600 mL original colloid (Ori) product was divided into two 
aliquots for the comparative analysis. Ultracentrifugation was performed at 7.8 x 103 g 
and 10°C for 90 min to separate the colloid into a supernatant (Csu) and a pellet (Cpl) of 
AgNPs. Cpl was resuspended in 10 mL of supernatant. For ultrafiltration, the colloid was 
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pumped through a 50 nm filter yielding a concentrate (50c; AgNPs > pore size) and a 
filtrate (50f; AgNPs < pore size) sample. The 50f sample was then pumped through a 100 
kD filter to produce a concentrated (100c) sample (Figure S1). 
Visual inspection, transmission electron microscopy (TEM), UV-Vis absorption, 
and flame atomic absorption spectrophotometry (FAAS) measurements on each sample 
revealed corroborating data that the ultrafiltration method was more efficient at specific 
size selection and concentration of AgNPs with minimal aggregation than 
ultracentrifugation (Fig. 1A, Table 1). The dramatic color change between Ori, Cpl, and 
100c confirms that darker, more opaque solutions contain larger particles with high levels 
of AgNP aggregation (Fig. 1A, column 1).5a, TEM micrographs (Fig. 1A, column 1) 
show that Ori is characteristic of moderately dispersed, lowly concentrated AgNPs. Cpl 
contains high concentrations of massive, heterogeneous AgNP-aggregates. 100c consists 
of highly concentrated yet lowly aggregated and homogenous AgNPs. The UV-Vis 
spectra show both Ori and 100c samples had surface plasmon resonance (SPR) 
absorption maximums at 400 nm, but 100c had a 10-fold higher intensity. This sharp, 
symmetrical peak is characteristic of small (10-20 nm diameter) and spherical AgNPs of 
low aggregation.5c,d The spectra for Cpl had a broader SPR peak with a clear shoulder, 
showing the ultracentrifugation process leads to the formation of polydisperse AgNP-
aggregrates. 
Size histograms (Fig. 1A, column 2) were prepared by analyzing the TEM 
micrographs of each sample (number of AgNPs = 500). The differences in size 
distribution and maximum diameters for the Ori and Cpl samples are significant (e.g., 
more than twice for Cpl) in comparison to the 100c sample. Most of the aggregates larger 
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than 20 nm were eliminated in 100c (Fig. 1, column 2), while Cpl had increased numbers 
of larger aggregates (5% of the total AgNPs have diameters 50 nm or larger). These large 
aggregates produced by ultracentrifugation accounted for 96% of the AgNP weight. 
Ultrafiltration was also 2.5-fold more efficient at concentrating the Ori colloid (from 77.4 
to 198.7 μg mL-1 of silver). Concentration factors for Cpl and 100c were 5.1- and 13.0-
fold, respectively (Table 1). 
Sample Ori Csu Cpl 50c 50f 100c 
Ave.  10.4 8.5 11.4 18.2 3.3 11 
Max. 141 54.4 161 162.5 87.3 60.5 
%Dist. 100 106 162 129 127 73 
Conc. 15.3 7.9 77.4 16.4 14.3 198.7 
 
Table 1. Specific characteristics of each AgNP preparation.  Average size in nm (Ave.), maximum size 
in nm (Max.), percent distribution (% Dist.), final concentration of silver in µg mL-1 (Conc.). 
 
The SERS-sensing efficiencies, the analytical (AEF) and surface enhancement 
factors (SEF), of Ori, Cpl and 100c were calculated by measuring the Raman, SERS, and 
fluorescence spectra of a 10-6 M rhodamine 6G (R6G) solution as a standard (Fig. 1B; 
Supporting Info).5c The AEF and SEF for Cpl and 100c were found to have similar values 
(e.g., AEF of 8.1 x 107 and SEF of 7.9 x 104 for 100c). These factors are 1,000-fold larger 
than those calculated for Ori. Recent studies5c showed that a SEF of 107 is sufficient to 
observe single-molecule SERS events for a R6G concentration of 10-9 M, at 632.8 nm, 
and with an integration time of 1s. The fluorescence data indicate that 100c and Cpl have 
comparable, improved R6G absorption abilities. Over 96% of the R6G molecules 
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effectively complexed to the AgNP surface and contribute to the SERS signal in 100c and 
Cpl (70% of the R6G probes for Ori). The enormous increase in signal for 100c is due to 
the highly concentrated, uniform colloidal AgNPs available for creating dimers or small 
AgNP-aggregates. Although the amount of silver is 2.5-fold less in Cpl, similar 
enhancement factors are achieved due to the large, heterogeneous AgNP-aggregates. 
However, the Cpl aggregates are formed in an uncontrolled manner and may impede 
























Figure 1. AgNPs were characterized at each step in the isolation and concentration process. A) Each row 
represents a distinct preparation: column 1) visual and TEM inspection photos, bar = 100 nm, column 2) 
size analysis from TEM data, and column 3) UV-Vis absorption spectra. B top) SERS spectra of R6G dye 





The data presented here demonstrate that ultrafiltration permits greater control 
over AgNP size, concentration and aggregation state than conventional methods of 
isolation such as ultracentrifugation. Future research studies and applications addressing 
the physiochemical properties or biological impact of AgNPs would greatly benefit from 
ultrafiltration for its ability to generate monodisperse colloidal NPs, to eliminate excess 
toxic chemicals from NP synthesis, and to obtain minimum levels of aggregation during 
NP concentration. The ultrafiltration method for AgNP isolation could tremendously 
boost the SERS-based sensing capabilities of these nanomaterials through the increased 
number of homogenous SERS hot spots available for a bio-target molecule within a 
minimal focal volume. Additionally, ultrafiltration could easily be implemented at 
various volume scales, for both research and industrial purposes. 
Supporting information available: Experimental methods and AEF/SEF calculations are 
available at http://pubs.acs.org. 
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MATERIALS AND METHODS 
Abbreviations 
R6G – rhodamine 6G; Colloidal Samples: Ori – Original, Csu – Ultracentrifuged 
supernatant, Cpl – Ultracentrifuged, 50f – 50 nm Ultrafiltered filtrate, 50c – 50 nm 
Ultrafiltered concentrate, and 100c –100kD Ultrafiltered. 
Experimental section 
All starting materials were purchased from commercial sources as analytical pure 
reagents. 
Chemicals and procedures 
Colloidal silver nanoparticles (AgNPs) synthesis 
A slightly modified Creighton1 colloid was produced by the borohydride 
reduction (NaBH4, Fisher Scientific) of silver nitrate (AgNO3, Fisher Scientific). Briefly, 
an AgNO3 solution (1.70 mg in 10.0 mL of highly purified water) cooled to 
approximately 10±2°C was added drop wise, with constant stirring, to a NaBH4 solution 
(4.53 mg in 60.0 mL of highly purified water) pre-cooled to 2±1°C. Stirring was 
continued for another 50 min in the ice bath. The colloid was then stored in refrigerator at 
4±1°C until use. 
Theoretical estimate of the amount of colloidal AgNPs 
In preparing the colloid, 1.70 mg of AgNO3, corresponding to 10-5 mols, were 
added to 10.0 mL of water and slowly mixed with 60.0 mL of a NaBH4 solution. 
Therefore, the final volume of colloid (70.0 mL) had a total silver mass of 1.08 x 10-3 g. 






Freshly synthesized AgNP suspensions were passed through 0.2 μm filters prior 
to purification (Nalgene Labware). A 300 mL volume of these pre-filtered AgNPs, which 
was obtained by combining several batches, was then used for processing by 
ultracentrifugation and tangential flow filtration methods. 
Ultracentrifugation 
All centrifugation was performed in a L8M-70 ultracentrifuge using a 45-Ti fixed 
angle rotor and a 70 mL bottle with cap assembly (Beckman Coulter). Samples were 
centrifuged at 10 °C, for 90 minutes at 7.8 x 103 g (10,000 rpm). Supernatants were 
removed using serological pipets. While decanting the supernatant, 10 mL were left 
within the centrifuge bottle. This remaining supernatant was used to resuspend the AgNP 





Figure S1. A schematic representation of the overall size selection and concentration processes. Samples 
taken at each step in the process are represented in boxes. Labeled arrows indicate the specific size 
selection and concentration step. 
 
Tangential Flow Filtration 
The filtering apparatus and equipment was assembled according to the 
manufacturer’s recommendations (Spectrum Laboratories, Rancho Dominguez, CA). 
Samples were filtered through a 50 nm Midi Kros module at a steady flow rate of 300 mL 
min-1 using the KrosFlo II Research System. The resulting filtrate’s volume, containing 
particles smaller than 50 nm (50f), was further filtered through a 100 kD Midi Kros 
module, while the concentrate volume (system holdup volume of 10 mL) was saved for 
analysis. The 100 kD filtrate, containing particles smaller than 100 kD (100f), and 
concentrate, containing particles larger than 100 kD (100c), volumes were likewise 
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retained for analysis. The filtering scheme is represented in Figure S1. Tubing and 
reservoirs were replaced or cleaned by washing three times with de-ionized water and 7x 
detergent (MP Bio), followed by three flushes of de-ionized water, between each filtering 
step. 
UV-Vis absorption spectrophotometry 
The absorption spectra, corresponding to innate surface plasmon resonances of 
AgNPs which indicate AgNP size and dispersity in solution, were recorded using an 8453 
UV-VIS-NIR (Hewlett Packard Inc.) spectrophotometer and a Cary 50 UV-VIS-NIR 
spectrophotometer (Varian Inc.) at 1 nm intervals. Each colloidal AgNPs sample was 
diluted with highly purified water (1:10 volume ratio) before measurement. A cell (Fisher 
Scientific) of a path length of 10.0 mm and a capacity of 4.5 mL was used for all 
measurements. 
Transmission Electron Microscopy (TEM) 
Samples were diluted in highly purified water when necessary. Twenty 
microliters of each sample were then deposited on 300-mesh formvar-coated gold grids 
(Electron Microscopy Sciences). Grids were left to dry in a desiccator and viewed within 
one day. A Phillips EM 208S transmission electron microscope operating at an 
accelerating potential of 70kV was used to visualize the nanoparticle samples before and 
after each step of the purification process. Electron micrographs were captured using a 
high resolution Gatan Bioscan camera. 
TEM image analysis 
Tagged image files were analyzed by ImagePro software (Media Cybernetics 
Inc.). Automated count settings were used to distinguish the light background from the 
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dark perimeter of the AgNPs. One particle was defined by a complete and enclosed 
perimeter. A minimum of 500 particles per sample were analyzed. The Microsoft Excel 
software was then used to bin and analyze the average particle diameter data collected 
from the micrographs. The Origin 8 software was then used to graphically represent the 
data. 
The average particle diameters for 50f and 100c were 3.3 nm and 11 nm, 
respectively. (Table 1 of the manuscript) This corresponding increase in average particle 
diameter is due to the increased counting frequency of particles with sizes between the 
upper and lower filter limits and the reduction in frequency of the smaller particles due to 
their passage through the filter. The larger particle frequency is increased due to large 
particle retention within the lumen of filter module. Concurrently there is a decrease in 
small particle frequency from their passage through the membrane and into the eluent or 
filtrate. Additionally, the maximum diameter of 60.5 nm for 100c was unexpected for the 
filter limit of 50 nm. In theory, all of the particles with diameters larger than 50 nm 
should have been removed from the 50f sample by their retention in the 50 nm filter. 
However, particles with maximum diameters larger than 50 nm can still exist in the 50f 
sample because they may be slightly non-spherical and have other dimensions less than 
50 nm allowing them to pass through the filter in the first filtering scheme (50 nm filter), 
but be retained in the second step (100 kD filter). This explanation applies to the 50f 
sample as well. 
Flame Atomic Absorption Spectroscopy (FAAS) 
An AA reference silver standard solution of 1.0 x 103 µg mL-1 was purchased 
from Fisher Scientific (Lot Number: CL4-132AG) and used for the preparation of six 
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silver standards of 0.1, 0.2, 0.5, 1.0, 2.0, and 4 µg mL-1. The FAAS calibration curve is 
depicted in Figure S2. Each sample contained 2% nitric acid (Optima grade, Fisher 
Scientific, Catalog #A467-500). Samples were diluted 100x (Ori, Csu, 50f) or 200x (Cpl, 
50c, 100c). 
 
Figure S2: Flame atomic absorption spectroscopy calibration curve constructed by using six silver 
standards of 0.1, 0.2, 0.5, 1.0, 2.0, and 4 ppm. 
 
A fast sequential atomic absorption spectrometer (model AA240 FS, Varian Inc.) 
equipped with an air-acetylene burner and a silver hollow cathode lamp (5 mA) was used 
for the determination of silver content within samples. The operating conditions were set 
as recommended by manufacturer: wavelength - 328.1 nm, slit width – 0.5 nm, air flow 
rate – 13.50 L min-1, and acetylene flow rate 2.00 L min-1. The acquisition time of each 
measurement was 5 s, and a delay time of 3 s was introduced in between measurements. 
Each sample was measured three times and the absorbance values were averaged before 
extrapolating the silver concentration from the calibration curve. A blank solution was 
introduced between each sample. 
Raman and SERS Spectroscopy 
A 10-3 M stock solution of the rhodamine 6G dye (R6G, Fisher Scientific) was 
prepared in water and further diluted to the desired concentrations. The SERS samples 
were obtained by adding 0.9 x 102 µL of the 2.22 x 10-6 M R6G solution and 0.1 x 102 µL 
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of the 1 M KBr (Fisher Scientific) solution to 1 mL of each of the colloidal samples (i.e, 
Ori, Csu, Cpl, 50c, 50f, and 100c). The final concentrations of KBr and R6G in the 
colloidal suspension were approximately 0.5 x 10-1 M and 10-6 M, respectively. 
The Raman and SERS measurements were performed using a LabRamHR 800 
system (Horiba Jobin Yvon Inc.) equipped with 1800 and 600 grooves/mm holographic 
gratings. The 633 nm output of a He-Ne laser was used as an excitation line. The laser 
output was 17 mW. The laser beam spot had a diameter of about 1 µm and was focused 
on the colloidal samples placed in cuvettes with the help of a high resolution confocal 
Raman microscope (high stability BX41) and a long working distance Olympus objective 
(50x). The confocal hole was set at 300 µm and the backscattered Raman signal was 
recorded using an open electrode thermo-electric cooled CCD detector (1024x526 
pixels). The spectral resolution was 1 cm-1. The acquisition times were a) 30 s for normal 
Raman measurements and b) 3 s (all samples except for 100c and Cpl) or 0.5 s (100c and 
Cpl) for SERS spectra. Each Raman and SERS spectral window was averaged over 3 and 
5 cycles, respectively. The Raman data were then analyzed and processed using the 
LabSpec 5 and Origin 8 software. A comparative graph showing the SERS spectra of Ori, 
Cpl, and 100c was prepared for Figure 1 of the manuscript after rescaling the intensities 
in the SERS spectrum of the original colloid (Ori) to compensate for the different 
acquisition times (3s for Ori and 0.5 s for 100c and Cpl). In this graph, the SERS spectra 
of Cpl and 100c were shifted on the Y scale (Raman Intensity) to allow for a direct 





The fluorescence emission spectra of all SERS samples and R6G solution (0.75 x 
10-6 M) were recorded in a fluorescence quartz cuvette using a Cary Eclipse fluorescence 
spectrophotometer (Varian Inc.). The 10-6 M solution of R6G caused detector saturation 
and could not be recorded. The excitation wavelength was 532 nm and the emission 
spectra were collected in the 540-700 nm range using a PMT detector voltage of 600 V at 




Figure S3. Overview of colloidal AgNP processing and characterization. AgNPs were characterized at 
each step in the ultracentrifugation (Csu and Cpl) and ultrafiltration (50c, 50f, and 100c) process, and 
compared with the original colloid (Ori). Each row represents a distinct preparation step: column 1) sample 
name, column 2) visual and TEM inspection photos, bar = 100 nm, column 3) size analysis of AgNPs from 
TEM data, column 4) UV-Vis absorption spectra, column 5) Raman (at 10-3 M) and SERS (at 10-6 M) 
spectra of R6G (The ordinary Raman spectrum of each colloidal sample was inserted as a control), and 
column 6) fluorescence emission spectra of each colloidal sample incubated with R6G at 10-6 M before and 
after centrifugation (supernatant) at 7.8 x 103 g and 10°C for 90 min (The fluorescence emission spectrum 




Analytical Enhancement Factor (AEF) and Surface Enhancement Factor (SEF) 
Estimates 
The AEF and SEF are the most important values for characterizing the SERS effect. 
The peaks at 1652 cm-1 of R6G (i.e., a streching of the R6G xanthine ring) and 3250-
3420 cm-1 of H2O (i.e., two broad bands corresponding to the symmetric and asymmetric 
water stretching modes) were chosen to estimate these factors using an excitation line of 
632.8 nm.2,3 After a baseline correction (User defined baseline anchor points: 10 points, 
Interpolation method: Bspline), the ratio of the integrated peak areas at 1652 cm-1 and at 
3380 cm-1 was determined for both, the Raman and SERS spectra of R6G (e.g., 
64
Raman  ,HRaman R6G, 10  06.2/10  26.2area Int./area Int. 2 ××=O  for the normal Raman 
spectrum of the 10-3M R6G solution). The non-SERS differential Raman cross-section of 
R6G ( Ωdd /Raman R6G,σ ) was included to obtain reliable and realistic enhancement factors. 
This aspect has often been ignored and is partially responsible for the unrealistically large 
enhancement factors sometimes reported in literature. Dyes such as R6G can have 
notably large differential Raman-cross sections2 even in non-resonance conditions due to 
pre-resonance effects2,3. The R6G dye has an absorption maximum at 528 nm and the 
excitation wavelength employed in this study was 632.8 nm. 
The non-SERS differential Raman cross section of R6G ( Ωdd /Raman  R6G,σ ) was 
determined using the following formula: 
























where Ωdd /Raman  R6G,σ  and Ωdd /Raman  O,H2σ  (
1230 cm 10  2.2 −− srx )3 are the differential 
normal Raman cross-sections of R6G and H2O, respectively, excited at 632.8 nm. 
Raman ,6GRC (10
-3 M) and Raman ,2OHC  (55.5 M) denote the molar concentrations of R6G and 
water, respectively. 
In this study, a non-SERS differential Raman cross section of 12-27 cm 10 x 3.1 −sr  
was obtained for the peak at 1652 cm-1 of R6G which agrees well with the one reported 
in literature.3 Although this cross-section is much larger than the value which Nie et al. 
had estimated in his single-molecule SERS study,4 it is similar to the experimental results 
in the literature ( 12-27 cm 10 x 4.4 −sr ).2,3 The differential Raman cross-section of R6G at 
resonance was recently predicted to be on the order of 12-25 cm 10 −sr .3,4 The large 
differential Raman cross section of R6G at nm 8.6320 =λ  is partially due to the 
relatively large size of the R6G molecule, but above all, it is the result of the pre-
resonance Raman effect (the excitation wavelength is close to the resonance 
wavelength).2,3 
A similar approach was used to calculate the differential SERS cross-section of 
R6G (e.g., 12-24SERS  R6G, cm 10 x 746.9/
−=Ω srddσ  for Ori) at an analyte concentration, 
SERS ,6GRC , of 10
-6 M foreach colloidal suspension (i.e., Ori, Cpl, and 100c). The water 
concentration, Raman ,2OHC , was maintained the same as for the normal Raman 
experiments. 
The AEF factor indicates how much more signal can be expected from SERS as 
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 (2) 
The different acquisition times for the Raman and SERS measurements of Ori, Cpl, and 
100c were also factored into the above formula (e.g., 30s/3s for Ori). All other 
experimental conditions were identical (i.e., microscope objective, lenses, spectrometer, 
cuvette, etc.) The values obtained for each colloidal sample are listed in Table S1. 
Although SERS ,6GRC  does not fully characterize the number of R6G molecules 
adsorbed AEF is useful for specific practical applications (e.g., colloidal solutions).  The 
AEF factor strongly depends on many parameters, in particular, on the adsorption 
properties and surface coverage of the dye probe. The AEF formula ignores that only the 
adsorbed probe molecules contribute to the SERS signal and that the enhancement effect 
is distance-dependent. Hence, the AEF factor does not offer a good characterization of 
the SERS substrate itself and it cannot be used to an absolute comparison term for the 
performance of different SERS substrates. AEF does represent a simple figure for SEF 
provided that submonolayer coverage is ensured. 
The absorption ability of the Ori, Cpl, and 100c colloidal samples towards the R6G 
probes were estimated in this study using fluorescence quenching experiments. It should 
be mentioned here that only the free R6G molecule in the colloidal suspension are able to 
contribute to the fluorescence intensity. The colloidal samples alone and their 
corresponding supernatants after the centrifugation process exhibited the same 
fluorescence intensities. 
The fluorescence emission spectra in Figure S3 show that the Ori, Cpl, and 100c 
colloidal samples incubated with R6G at a 10-6 M concentration present a significant 
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decrease in fluorescence intensity ( colloidin  6GRI ) in comparison with their corresponding 
supernatants collected after ultracentrifugation ( tsupernatan  colloidin  6GRI ). The decreased 
intensity is due to the inability of R6G molecules to fluoresce because of their absorption 
on the AgNP surface. As expected, dramatic fluorescence intensity reductions were 
noticed for Cpl and 100c due to the increased number of AgNPs available to adsorb the 
R6G dye molecules within the same volume when compared to Ori. The actual number 
of R6G molecules ( surfaceAgNPGRC  on   6 ) contributing to the observed SERS enhanced signal 
(Table 1) was calculated using equation (3) based on the observed changes in intensity 
and the fluorescence intensity of the R6G bulk solution ( solution  6 bulkGRI ) as a reference. The 
difference in concentration for the R6G solution in the bulk solution (0.75 x 10-6 M) and 
the colloid (10-6 M) was also factored in. 
%)100 x  
M 10
M 0.75x10 x-(100% x M10 6-
-6
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The SEF factors were then determined according to the following equation: 




=        
 (4) 
where surfaceAgNPGRC   on   6  and solution  in   6 bulkGRC  are the number of R6G molecules on the 




Sample % of R6G molecules  
contributing to SERS signal 
AEF SEF 
Ori 70 7.3 x 104 5.1 x 101 
Cpl 97 7.0 x 107 6.7 x 104 
100c 96 8.1 x 107 7.9 x 104 
 
Table S1. Analytical (AEF) and surface (SEF) enhancement factors estimated at an R6G analyte 
concentration of 10-6 M and an excitation wavelength of 632.8 nm. 
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A High-throughput Screen for Nanotechnology-based Antiviral Agents as Demonstrated 
with Silver Nanoparticles 
 
ABSTRACT 
Nanotechnology offers untapped potential into the development of novel antiviral 
agents; however, no technology exists to screen these new materials for antiviral activity 
in a high-throughput format.  To address this issue a new assay was developed that 
combines a cellular proliferation assay with a viral vector system to simultaneously 
measure antiviral activity and cytotoxicity of nanomaterials. Silver nanoparticles, 
currently generating broad interest and increasing commercial presence as antimicrobials, 
were chosen to test the new assay’s ability to measure antiviral activity in addition to 
charting the new assays sensitivity in parallel with traditional methods.  This new assay 
was sensitive to viral inhibition spanning 99% of the infectious titer generated with the 
viral vector system. Significant antiviral activity of silver nanoparticles was observed at 
doses as low as 2 μg mL-1, while cytotoxicity was found only at doses ≥ 500 μg mL -1, 
without reaching the LD50. These results reveal a sensitive and innovative method for 





Nanotechnology is currently a hotbed of interest for the development of 
commercial applications, in particular the discovery of novel antimicrobial agents. Many 
different nanomaterials have demonstrated innate antibacterial activity but little research 
exists on their antiviral potential. An explanation for the understudied antiviral properties 
of nanomaterials stems from the lack of established methods to screen the antiviral 
activity of nanomaterials, especially in a high-throughput format.  
Defined as having one dimension between 1 and 100 nm, nanomaterials are 
characteristically distinct from their bulk and ionic counterparts due to their large surface-
to-volume ratios and unique reactivities. Silver nanoparticles (AgNPs), in particular, were 
chosen for the current study because they have demonstrated antimicrobial properties (5, 
15, 21, 22). Silver, in its ionic form, has been used as an antimicrobial for millennia with 
little known resistance, and the emergence of nanotechnology has generated new interest 
in the development of silver as a potent antimicrobial in the post-antimicrobial resistance 
era. AgNPs are gaining critical attention due to their ever-increasing commercial 
presence, despite the unknown mechanisms for their antimicrobial action and potential 
for cytotoxic effects (7, 10, 17, 23).  
In order to accurately gauge the potential of nanomaterials as an antiviral agent, a 
new assay was successfully developed to measure inhibition of viral infection while 
simultaneously charting the toxicity of the nanomaterial itself. Traditional colony 
forming unit (CFU) assays for viruses, based on the transduction of a selective marker 
through a non-lytic virus, are cumbersome and impractical for screening large numbers of 
drugs at multiple doses. The new assay, based on the standard 3-(4,5-dimethylthiazol-2-
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yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assay employs a high-
throughput, small-scale format that will be more efficient and economical, thus enabling 
more in depth investigations of nanomaterials as antiviral agents.   
MATERIALS AND METHODS 
Nanoparticle Characterization 
Spherical, 25 nm diameter AgNPs were used (NovaCentrix, Austin, TX). The 
AgNPs were 99.9% pure silver as determined by induction-coupled plasma spectroscopy 
performed by NovaCentrix. Transmission electron microscopy (TEM) was conducted to 
confirm size and morphology using a Philips EM 208S operating at 70kV (Royal Philips 
Electronics, NL; Fig. 1A). AgNPs were negatively stained with 3% uranyl acetate to test 
for organic capping agents or impurities bound to the particles’ surfaces (Fig. 1B). 
Analysis of TEM images was accomplished using Image-Pro 6.2 software (Media 
Cybernetics, Inc., Bethesda, MD). Specifically, size measurements were performed by 
allowing the software to automatically define the perimeter of each nanoparticle, and then 
calculate the average of multiple diameter measurements for each particle. Prior to use in 
viral inhibition assays or particle characterization, AgNPs were sonicated for 30 seconds 
using a Misonix S-4000 ultrasonic liquid processor, with a 419 microtip probe attachment 
(Misonix, Inc., Farmingdale, NY).  
Antiviral Assay 
An assay originally developed for measuring HIV-1 mutation rate was modified 
for high-throughput screening of nanoparticle antiviral activity (8). This assay uses an 
HIV-1 vector system that measures a single cycle of viral replication through the point of 
proviral gene expression. The HIV-1 particle carries the hygromycin-B resistance gene 
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for selection and the envelope protein of Vesicular stomatitis virus (VSV), a species of 
virus from the Rhabdoviridae family that enters cells by a pH-dependent fusion 
mechanism mediated by the envelope protein. This viral pseudotype was produced by 
transient transfection of three separate plasmids as previously described (8). Briefly, 3 μg 
of the viral vector backbone (∆gag -pol), 1 μg of the VSV-glycoprotein and 3 μg of the 
helper plasmid containing gag-pol were transfected via Lipofectamine2000™ 
(Invitrogen, Carlsbad, CA) into 293T/17 cells (ATCC, Manassas, VA) following the 
Invitrogen’s protocol.  293T/17 cells were plated at 2 x 105 cells in 60 mm2 dishes 24 
hours prior to transfection. Forty-eight hours post transfection the supernatant containing 
the infectious yet replication deficient viral vector, was harvested and used immediately 
for infections. 
Infections for the nanoparticle screen were modified from the previous study by 
using a quantity of virus equal to or greater than 2.5 times the tissue culture infectious 
dose 50% (TCID50) as determined by the Karber method (11). Infections were performed 
in 96-well microtiter plates containing Vero76 cells (ATCC, Manassas, VA) at a density 
of 1 x 104 cells per well, plated 24 hours prior to infection. Varying AgNP 
concentrations, prepared in serum-free cell medium, were mixed 1:1 with fresh, not 
previously frozen, virus stock for one hour at 37°C. After one hour, medium was 
aspirated from each well and a 50 μL volume of the virus-AgNP mixture was applied to 
the appropriate wells. The infection mixture was incubated at 37°C for one hour and 
removed from the monolayer by aspiration. A final volume of 200 μL of medium was 
added to each well. Twenty-four hours post-infection, a 200 μL volume of medium 
containing 400 μg mL-1 hygromycin-B (Hyg) was added to each infected well and to the 
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uninfected selective medium positive control wells. Negative control wells, containing 
uninfected cells incubated with each AgNP concentration, were given 200 μL of normal, 
non-selective medium. The medium was replaced in this manner every four days for two 
weeks to allow for the selective effects of Hyg. 
A cytotoxic assay was conducted after the two-week Hyg selection period to 
quantify viral infection using the chemical MTT as the colorimetric reagent and 0.04 N 
HCl in isopropanol as the stop solution (16). Trypsin was used as part of the protocol to 
disrupt colonies and allow cell exposure to the MTT chemical. The optical density (OD) 
was measured at 570 nm using a Dynatech Laboratories MRX automated plate reader 
(Dynex, Richfield MN). A One-way ANOVA statistical analysis of the MTT results from 
three independent experiments was performed using SigmaPlot 11.0 software comparing 
each dose to the untreated control (Systat Software, Inc., San Jose, CA). P-values of less 
than 0.050 were considered statistically significant. For each experiment, traditional 
colony-forming unit (CFU) assays were performed in parallel as previously described to 
quantify the viral titer and ensure sensitivity in the new assay (8). Briefly, the freshly 
harvested virus was serially diluted 10-fold, from the undiluted stock down to a dilution 
of 10-4, and each 10-fold dilution was used to infect Vero 76 cells, which were plated out 
at 5 x 105 cells in 60 mm2 dishes 24 hours prior to infection. The infection took place for 
one hour then infection dilutions were aspirated and replaced with non-selective medium 
and incubated at 37°C overnight. After 24 hours the medium was changed to selective 
media containing Hyg.  The medium was aspirated and replaced every four days for two 






AgNPs were evaluated via TEM for size, morphology, and surface coatings (Fig. 
1A). Multiple TEM images selected at random from separate preparations were analyzed 
and over 200 particles were measured to confirm the AgNPs were generally spherical 
with an average diameter of 25 nm ± 10 nm. Negative staining of AgNPs with uranyl 
acetate demonstrated that the particles were completely surrounded by the heavy metal 
stain, gradual darkening up to the perimeter of the nanoparticle, indicating that there were 
no organic surface modifications such as surfactants or capping agents (Fig. 1B). If 
organic surface modifications were present the gradual darkening surrounding each 
nanoparticle would be interrupted by a relatively white-colored halo superficial to the 
dark nanoparticles’ perimeter. 
 
Figure 1. Transmission electron micrographs of AgNPs. A) Unstained AgNPs applied to Formvar coated 
grid were analyzed for morphology and size, bar = 100 nm. B) AgNPs negatively stained with 3% uranyl 
acetate to detect organic surface modifications, bar = 0.2 μm. 
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Antiviral Assay Validation 
Viral titers obtained from the new assay were compared to those obtained from 
the traditional CFU assay in order to validate the new drug-screening platform. As can be 
seen in Fig. 2, the OD readings from the new assay correlated well with the CFU output 
of the traditional assay. Two representative fresh virus stocks harvested immediately after 
the transfection period (one high and one low titer) were chosen for the comparison. The 
titers of these virus stocks were 10-fold apart as measured by the traditional CFU assay (1 
x 104 and 1 x 103 CFU mL-1 for the high and low titer stocks, respectively), which made 
for a convenient comparison. In agreement with theoretical prediction, when the high-
titer virus stock was diluted by 10-fold, it yielded a similar OD reading to that of the 
undiluted low-titer stock, (compare open circle at dilution 10-1 with closed circle at 
undiluted, Fig. 2). Similarly, when diluted by 100-fold, the high-titer stock gave a similar 
OD reading to that of the 10-fold dilution of the low titer stock (compare open circle at 
dilution 10-2 with closed circle at dilution 10-1, Fig. 2). The 100-fold dilution of the low-
titer stock reached the cut-off OD value of 0.3 for the MTT assay, i.e. it was out of the 
linear range on the lower end (closed circle at dilution 10-2, Fig. 2), and did not follow the 
same correlation trend. The new assay accurately detected changes in infectious virus 
over 99 % of the total infectious viral titer generated. The uninfected cell control (closed 
triangle at undiluted, Fig. 2) showed a similar OD as compared with the undiluted high 
titer virus stock (open circle, Fig. 2), suggesting that both conditions had reached 





Figure 2. Correlation of viral titers obtained by optical density and colony forming unit readout. Fresh 
virus stocks were measured in parallel using the new MTT-based assay versus the traditional CFU-based 
assay. 
Nanoparticle Antiviral Activity 
The antiviral activity of individual AgNP preparations was measured using the 
MTT-based assay with three independent, fresh virus stocks (n = 3, Fig. 3). A 
cytotoxicity assay was performed simultaneously with the antiviral measurement in the 
same microtiter plate wherein cells were incubated in a non-selective medium with the 
same doses of AgNPs without the addition of virus (Fig. 3). The AgNPs exhibited 
statistically significant antiviral activity at doses as low as 2 μg mL-1 (p = 0.005). The 
minimum inhibitory concentration 50% (IC50) of AgNPs against the virus was 16 μg mL-
1. No false OD readings produced by AgNP reduction of MTT were observed in control 
experiments where MTT was incubated with various AgNP concentrations (data not 
shown). Cytotoxicity was insignificant, as demonstrated by one-way ANOVA, at all 
doses up through 250 μg mL-1(p = ≥ 0.340 at 250 μg mL -1). Significant AgNP 
cytotoxicity was observed beginning at 500 μg mL-1 (p = 0.020). The increasing variation 
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associated with the higher concentrations of AgNPs was a consequence of cells reacting 
differently to these AgNP concentrations between experiments. However, even at the 
highest dose tested (1,000 μg mL-1, data not shown), toxicity against the cells did not 
reach the lethal dose 50% (LD50). Thus, the therapeutic index for the AgNPs is greater 
than 63 as calculated by dividing the LD50 by the IC50. 
 
 
Figure 3. AgNP antiviral activity and cytotoxicity. The new MTT-based assay was used to assess antiviral 
activity and cytotoxicity across a range of AgNP concentrations. Data are represented as percent of 
infected, untreated controls. Asterisks above the symbols represent values that were statistically significant  
compared to the untreated control, as measured by one-way ANOVA for either the antiviral measurements 




Many different tetrazolium-based assays exist for determining cell viability based 
on metabolic activity. The assay described here utilizes MTT, which has been shown to 
have advantages over other cytotoxicity assays due to its decreased evaporation errors, 
low variability, and high sensitivity in 14-day cultures (4, 9, 18, 20). Since MTT is 
reduced in the cytoplasm instead of at the plasma membrane surface, the chances that 
nanomaterials bound to the cell surface will interfere with the chemical reduction of the 
salt or the uptake of other dyes, such as neutral red (1).  
Another advantage of MTT-based screening methods for AgNPs and other 
metallic nanomaterials is the lack of interference with surface plasmon resonances 
(SPRs), an innate physical property of metal nanoparticles responsible for their 
characteristic colors, which can interfere with the OD readings of other cytotoxicity 
assays, typically performed in the 400-500 nm range. The OD reading of the MTT assay 
is performed at a wavelength of 570 nm, well past the characteristic SPR absorbance of 
AgNPs (~400 nm) and unaggregated AgNPs less than 30 nm should not demonstrate 
significant absorbances via SPR at 570 nm (6, 13). This new antiviral assay would also 
be adaptable for nanoparticles with SPRs around 570 nm as it would be easy to simply 
utilize a relative of MTT, such as MTS, XTT or WST-1, which absorb at different 
wavelengths. Dye-based cytoxicity assays, including MTT and its chemical relatives, 
have been shown to be problematic for certain carbon-based nanoparticles, particularly 
carbon nanotubes (2, 14, 25). However, a recent study showed that the MTT assay 
performed well with a non-carbon, metallic nanomaterial (quantum dots) indicating that 
tetrazolium based assays are a legitimate means for detecting cellular viability and thus 
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antiviral activity of nanomaterials when coupled with this method (14). The multiple 
media changes that occur over the course of the new assay further reduce the chance that 
nanomaterials will interfere with the OD readings because unbound nanomaterials are 
washed away. MTT has also been shown to be superior to lactate dehydogenase and 
trypan blue exclusion assays for determining cell viability, and thus antiviral activity 
when coupled with this new method (3).  
MTT-based assays have been used for determining cytotoxicity, viral titers, and 
antiviral activity through cytopathic effects (CPE) for over 20 years (19). In fact, the 
National Cancer Institute lists an MTT-based assay as a standard method for 
characterizing nanomaterial cytotoxicity (24). Utilizing this standard tetrazolium based 
assay to detect antiviral activity, in addition to cytotoxicity, eliminates the possibility of 
translating cytotoxic effects of the nanomaterial as antiviral activity during traditional 
plaque forming unit (PFU) or CFU methods with replication competent viruses. To the 
authors’ knowledge this assay is the first of its kind to replicate the traditional CFU assay, 
or reduction/neutralization tests, in high-throughput, 96-well plate format for the 
purposes of screening antiviral activity. The widespread use of the MTT platform, in 
general, suggests that many laboratories have the required automation capabilities, tools, 
and reagents to carry out the new assay described within this communication. 
Multiple concentrations of AgNPs incubated with the virus were used to 
determine their antiviral activity. Existing technology, such as the traditional CFU and 
PFU assays, are labor intensive and as a result do not permit easy examination of various 
doses. This new assay serves as a preliminary screen for antiviral activity as well as a 
rudimentary indicator of a possible antiviral mechanism. If antiviral activity is detected 
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these results will then warrant further examination for the mechanism of antiviral 
activity, post-exposure efficacy, multiplicity of nanoparticles (MON) required to inhibit 
infection, cytoprotective effects of the nanomaterial and the MON required for possible 
cytoprotective effects. 
A recent report suggests that inhibition of HIV-1 by AgNPs occurs at an early 
stage of infection (12). The current assay supports this data by allowing for mechanistic 
studies in the critical early stage of infection; later events in the viral replication cycle are 
intentionally blocked through genetic engineering of the virus (8). Furthermore, CPE 
normally associated with late-stage HIV-1 infection are eliminated, allowing for 
proliferation to be measured. In this way, CPE of the virus is not mistaken for 
nanoparticle cytotoxicity. 
The viral pseudotyping system employed in the current study broadens the utility 
of the new assay and provides standardization. Many different viral envelope proteins can 
be placed on the outside of the HIV-1 particle to simulate infection for different viruses. 
This interchangeable envelope protein is additionally advantageous through its ability to 
simulate, at lower levels of biocontainment, viruses normally studied under 
biocontainment levels 3 and 4. This pseudotyping adaptability ensures that varying levels 
of CPE that might be associated with the parental viruses are not falsely interpreted as 
enhanced or reduced antiviral activity against the simulated virions when comparing 
prospective new agents. 
CONCLUSIONS 
A new high-throughput screening assay was successfully developed and used to 
simultaneously measure the antiviral activity and cytotoxicity of nanomaterials in a cell 
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culture-based system creating a new system by which nanomaterials can be screened for 
antiviral activity. Furthermore, the results of this assay can serve as a “finger in the 
wind,” from which the direction of future mechanistic studies of nanomaterial antiviral 
activity. In the process of validating this new assay with a contemporary nanomaterial, 
silver nanoparticles showed clear-cut antiviral effects and low cytotoxicity, 
demonstrating a potential treatment with a high therapeutic index. The AgNPs inhibited 
the virus at an early stage of replication prior to assembly of new particles in the cell. 
Further investigation into the mechanism of nanoparticle antiviral activity is warranted. 
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Silver Nanoparticles Inhibit Vaccinia Virus Infection by Preventing Viral Entry 
 
ABSTRACT 
Nanotechnology, specifically silver nanoparticles (AgNPs), have gained 
tremendous attention and increasing presence in consumer products for their 
antimicrobial properties despite defined mechanisms of activity. Vaccinia virus (VACV), 
is a common analog for the study of Variola major, a Category A pathogen and a high 
priority for the development of effective antiviral agents. This study hypothesized that 
AgNPs inhibit VACV infection by preventing viral entry. A VACV reporter assay, 
designed specifically for the viral entry window, demonstrated that AgNPs significantly 
prevent VACV entry at doses as low as 8 μg mL-1 with an IC50 value as low as 48 μg mL-
1. Confocal microscopy confirmed the anti-entry effect of AgNPs, with significant 
inhibition as low as 32 μg mL-1. AgNPs prevented both direct fusion and 
macropinocytosis-dependent entry of VACV in a virucidal capacity. Western blot data 
suggested that AgNPs may bind directly to the entry fusion complex of VACV at anti-
entry concentrations revealing a potential virucidal mechanism. Inhibition of entry was 
demonstrated at non-cytotoxic doses as determined by MTT and trypan-blue exclusion 
assay. Observations were made for an additional mechanism of AgNP antiviral activity 
based on the loss of AgNP anti-entry effects after knockdown of Pak1, a vital component 
of macropinocytosis. Furthermore, plaque assays demonstrated AgNP inhibition of the 
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entire VACV replication cycle. These data suggest that AgNPs could be a potent antiviral 




Nanotechnology, an emerging field of research for materials with one dimension 
between 1 and 100 nm, is generating a significant presence among new commercially 
available products with the general public recognizing it as a buzzword and the scientific 
community presently hard at work discovering new applications. Metal nanoparticles, 
particularly silver nanoparticles (AgNPs), have received tremendous attention recently 
for their observed antimicrobial properties. Applications utilizing AgNPs have multiplied 
over 1,000% since 2006 with AgNPs representing 313 of the 1317 licensed 
nanotechnology products (55). Most of the commercial applications for AgNPs are 
antimicrobial; for example, AgNPs are commercially available as preservatives (i.e. 
clothing and cosmetics), medical devices (i.e. coatings for catheters and wound 
dressings), and as water treatment agents with no defined mechanism for their 
antimicrobial properties (11, 17, 39).  
AgNP antimicrobial activity is a rapidly expanding new field of research and 
development due to the benefits this technology can provide. For example, because they 
are a metal, AgNPs are highly resilient to changes in temperature and humidity relative to 
traditional antimicrobials. AgNPs also have an advantage over traditional antibiotics and 
antivirals in their lack of microbial resistance. In addition to the benefits over traditional 
antibacterial and antiviral agents, AgNPs have been observed to exert antimicrobial 
effects on a wide range of bacteria and viruses, making AgNPs a true broad-spectrum 
antimicrobial (32). Since an exponentially increasing number of products are approved 
for public consumption each year, this study sought to understand the mechanisms behind 
AgNP mediated antiviral activity, for which these products are marketed.  
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AgNPs exhibit large surface to volume ratio and low coordination numbers that 
result in enhanced catalytic and reactive abilities which lead to their antimicrobial activity 
(5, 50). AgNPs bind to biological material non-specifically through their inherent 
requirement for steric and electrostatic stabilization as a result of their highly polarized 
surfaces and empty S1 orbital at the zero valent state (5, 30). Covalent bonds are thus 
easily established, with complexes containing nitrogen (amines/protein), phosphorus 
(phosphanes/DNA) and sulfur (thiols/protein) being common electron donors (5). 
Various mechanisms for the antimicrobial properties of AgNPs have been 
proposed (38, 40). However, these studies mostly examined the antibacterial properties of 
AgNPs. Relatively little data is available for the mechanism of AgNP antiviral activity, 
which could differ drastically due to the inherent differences between bacteria and 
viruses. The antiviral activity of AgNPs has been documented in many different viral 
species including the human pathogens HIV-1, HBV, MPV and TCRV (12, 21, 23, 34, 
41). Each study suggested that an early event in viral infection is the likely point of 
AgNP antiviral activity. 
Variola major, an Orthopoxvirus and the causative agent of smallpox, is a 
Category A pathogen and a growing concern as a potential biological weapon due to 
decreased population immunity as a result of the cessation of vaccination. Study of 
Variola major virus is restricted to only one location within the United States. However, 
an accurate analog for the study of Variola major is available in the form of the virus 
used as the vaccine for smallpox, Vaccinia virus (VACV). Due to the similarities with 
Variola major and its use in vaccination, VACV has become the gold standard for 
research on Orthopoxviruses. Multiple government agencies have listed the development 
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therapeutics for Category A pathogens a high priority, which makes VACV an attractive 
target for investigations into the antiviral activity of AgNPs (49). 
VACV is a double stranded DNA virus of about 200kb and it replicates solely in 
the host cell cytoplasm. The large genome encodes almost all of the structural proteins 
and enzymes required to complete its replication process (9). There are two infectious 
forms of VACV: the mature virion (MV) and the extracellular virion, which differ from 
each other by the number of envelope membranes and a few proteins (33). This study will 
focus on the MV form of VACV. The infection process begins with VACV adsorption to 
the membrane of a permissible host cell. This binding to the cell surface is accomplished 
through VACV membrane proteins A27 and H3, D8, L1 and A26, which bind heparan 
sulphate, chondroitin sulphate, and laminin respectively (8, 13, 15, 22, 31, 52). At this 
stage in the infection process the virion is bound to the cell surface but has not yet 
entered the cell. 
VACV demonstrates two methods of entry, which makes it an ideal candidate for 
the investigation, because these methods can be independently assessed for a better 
understanding of AgNP mediated anti-entry effects. Both entry methods are dependent on 
a set of entry fusion complex proteins. Entry of VACV via the entry fusion complex 
(EFC) has been demonstrated at both neutral and low pH (4, 37, 51). Identified as a 
complex of proteins, the EFC is composed of A16, A21, A28, F9, G3, G9, H2, I2, J5, L1, 
L5, and O3, with nine out of twelve of these proteins considered integral members of the 
EFC as their disruption or removal destabilizes the complex (4, 6, 16, 27-29, 36, 44, 45, 
48, 54). The stoichiometry of the complex and its precise mechanism of action have yet 
to be classified or determined (53).  
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Entry into the host cell is broadly characterized as the delivery of the virion core 
to the cytoplasm. The viral core comes equipped with all the enzymes necessary to begin 
early transcription (33). Once the viral core has entered the cytoplasm, it immediately 
begins to transcribe early genes (7). This process has been documented to occur within 
the first six hours of infection and is measurable via reporter assay with protein 
expression driven by a constitutive early/late promoter (16, 52).  One pathway for VACV 
entry is acid-mediated and dependent on macropinocytosis (10, 43, 46). Additionally, 
VACV adsorption induces the activation of mediators for macropinocytosis, such as the 
serine-threonine kinase p21 activated kinase 1 (Pak1); without this cellular signaling 
component there is little to no macropinocytotic uptake of VACV (25). The other mode 
of VACV entry is direct fusion of the virion membrane with the plasma membrane (8, 31, 
46). Both methods are dependent on the correct function of the EFC. 
A mechanism through which viral infection is inhibited by AgNPs has yet to be 
determined. This study investigates the hypothesis that AgNPs exert their antiviral 
activity by preventing viral entry. VACV was chosen as the viral system to test this 
hypothesis due to the increased concern of the use of its close relative Variola major in a 
potential bioweapon and the call for the development of therapeutics for Category A 
pathogens. Also, VACV demonstrates multiple methods of cellular entry, which can be 






MATERIALS AND METHODS 
Antibodies, cell lines, nanoparticles and viruses. 
The BS-C-1 (CCL-26), Vero 76 (CRL-1587) and HeLa (CCL-2) cell lines were 
acquired form American Type Culture Collection (Manassas, VA) and grown according 
to manufacturer recommendations. All infections were performed with VACV in the MV 
form. Powdered AgNPs, certified 99.99% pure silver and average 25 nm in diameter, 
were acquired from NovaCentrix Inc. (Austin, TX) and further characterized as 
previously described (Chapter III, Figure 1). NovaCentrix particles were used for every 
experiment unless otherwise noted. Prior to use, NovaCentrix AgNPs were suspended in 
ultrapure water and sonicated for 30 seconds via Misonix S-4000 ultrasonic liquid 
processor equipped with a 419 microtip probe (Misonix Inc., Farmingdale, NY). AgNPs 
were then diluted, in complete growth medium, to their desired concentrations for each 
assay. Tangential flow ultrafiltered AgNPs were prepared and characterized as previously 
described and diluted in complete growth medium (47). Vaccinia immune globulin (NR-
2632) was acquired from BEI Rescourses (Manassas, VA). Rabbit-anti-Pak1 monoclonal 
antibody (2602S) was acquired from Cell Signaling Technology (Beverly, VA) and used 
according to manufacturer specifications. Rabbit-anti-β-actin monoclonal antibody 
(#4970S) was acquired from Cell Signaling Technology and used as per manufacturer 
instructions. Donkey-anti-rabbit polyclonal secondary antibody conjugated to horseradish 
peroxidase was acquired from Thermo-Fisher-Pierce (#SA1200, Pittsburgh, PA) and used 
according to manufacturer specifications. Rabbit-anti-G9 polyclonal antibody was 
acquired from AbCam (#ab93828, Cambridge, UK) and used according to company 
specifications. vSC56, a genetically engineered Western Reserve strain of VACV 
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expressing β-galactosidase (β-gal) under the control of a constitutively active early/late 
promoter in place of the TK gene, was a generous gift from Dr. Hanna Golding at The 
Food and Drug Administration (24). WR-A4-GFP, a Western Reserve strain of VACV 
genetically engineered with its A4 core protein fused to GFP, was a generous gift of Dr. 
Bernard Moss at the National Institute for Allergy and Infectious Disease (3).  
Viral stock preparation. 
All viruses used in this study were propagated by infecting HeLa monolayers 
grown to confluence in T-150 flasks (CLS430825-50EA, Sigma-Aldrich Corp., St. Louis, 
MO). Monolayers were harvested after reaching >90 % cytopathic effects then detached 
with sterile glass beads. The supernatant was then collected with the culture medium in 
50 cc conical tubes and centrifuged for 5 minutes at 514 x g. The supernatant was 
discarded and the cell pellet was resuspended in 5 mL of PBS and subjected to three 
rounds of rapid freeze-thaw via dry ice/ethanol bath and 37°C water bath to free MVs 
trapped within the cells and to disrupt the outer membrane of extracellular virions. Cell 
debris was then cleared from the lysates by centrifugation for 5 minutes at 514 x g. The 
supernatant was then collected and syringe filtered through a 0.45 μm filter. The viral 
suspension was then aliqouted and stored at –70°C until use.  
Viral titering.  
All viral titering experiments were performed on the BS-C-1 cell line in 6-well 
plates seeded at 5 x105 cells per well 24 hours prior to infection. On the day of infection 
the virus to be titered was diluted in 10-fold serial dilutions in serum free medium and 
500 μL of each dilution used to infect the monolayer for 2 hours. After two hours, the 
infection mix was aspirated and the monolayers overlaid with 2 mL of 1.25 % SeaPlaque 
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agarose (Lonza Rockland Inc., Rockland, MD) in complete growth medium. Once the 
overlay solidified at room temperature the plates were incubated at 37°C for 2 days at 
which time 200 μL of a 1.66 mg mL-1 solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was then dropped on top of the agarose overlay to 
stain live cells purple and provide contrast for the identification of plaques. Plates were 
then further incubated at 37°C for 4 hours to let the stain develop and then plaques were 
counted.  
Plaque assay for virion absorption. 
Vero76 and BS-C-1 cells were plated at 5 x 105 cells per well in each well of a 6-
well plate 24 hours prior to the day of the assay. On the day of the experiment WR-A4-
GFP at 8.6 x 109 pfu mL-1 was serially diluted 10-fold and exposed to 0, 8, 32, and 128 
μg mL-1 of AgNPs for 1 hour at 37°C. After one hour, Vero 76 cells and the AgNP/WR-
A4-GFP mixtures were then cooled to 4°C on ice for 30 minutes in order to prevent viral 
entry. The chilled AgNP/WR-A4-GFP mixture was used to infect the Vero 76 
monolayers on ice for 1 hour. After 1 hour, the monolayers were washed three times with 
ice cold PBS and brought to a final volume of 2 mL PBS after washing. Vero 76 
monolayers were then detached from the plate by scraping and collected in 50 cc conical 
tubes. Cells were then lysed by rapid freeze-thaw three times in a dry ice/ethanol bath, 
followed by 37°C water bath. After cells were lysed, the lysates were then serially diluted 
10-fold and subjected to viral titering on the BS-C-1 cells plated 24 hours previously, as 





Confocal virion adsorption assay. 
Vero 76 cells were plated at a density of 5 x 105 cells per well on glass cover slips 
added to the bottom of 6-well plates 24 hours prior to infection. On the day of the 
experiment WR-A4-GFP was diluted to a multiplicity of infection (MOI) of 1,000 in 
complete growth medium containing 0, 8, 32, and 128 μg mL-1 of AgNPs and incubated 
at 37°C for 1 hour. After 1 hour the AgNP/WR-A4-GFP mixture was then chilled to 4°C 
along with the cells and culture medium for 30 mintues. Once the cells were chilled they 
were infected with the AgNP/WR-A4-GFP mixtures on ice for 1 hour. After one hour, 
the infection mixture was removed and the cover slips incubated with 5 μM CellTracker 
Red CMPTX (Invitrogen, Carlsbad, CA) for 20 minutes on ice then aspirated and washed 
with ice cold PBS prior to 30 minutes of fixation with ice cold 3.7% formaldehyde in 
PBS. Cover slips were then mounted and examined as described in “Confocal entry assay 
for fluorescent VACV.” 
β-galactosidase entry assay. 
The β-gal entry assay was based on a protocol developed by the FDA to measure 
VACV neutralization after vaccination but modified to make it specific for detecting 
VACV entry (24). All aspects of the β-gal entry assay were identical to those described 
previously, except the following which made the assay specific for VACV entry (24): 
Vero 76 cells were plated at 2.5 x 105 cells per well in a 12-well plate 24 hours prior to 
initiating the assay. On the day of the assay, vSC56 was diluted to an MOI of 10 in 
complete medium and incubated with various AgNP concentrations for 1 hour prior to 
use for the virucidal condition. For the cytoprotective condition, cells were treated with 
AgNP concentrations, at 2-fold incriments from 2 to 256 μg mL-1, for 1 hour then 
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aspirated prior to infection with untreated vSC56. The AgNP/VACV mixture was then 
added to the cells for the virucidal condition or untreated vSC56 was added to previously 
AgNP treated cells for the cytoprotective condition. The infection was then carried out 
for 4 hours, at which time each well was aspirated then trypsinized with 0.25% trypsin in 
Hank’s Balanced Salt Solution. The trypsin was inactivated by the addition of an equal 
volume of complete medium and the detached cell suspension was collected in a 1.5 mL 
tube then centrifuged at 0.3 x g for 5 minutes. The supernatant was discarded and the cell 
pellet was then lysed with 4 % IGEPAL CA-630 in complete growth medium for a period 
of 1 hour at 37°C. Optical Densities collected at 570 nm on a Dynex MRXe Revelation 
plate reader (Dynex Inc., Chantilly, VA) were then used to calculate the percent of 
untreated control for each sample. For β-gal assays accompanied by a knockdown of 
Pak1, cells were plated out at 2.5 x 105 cells per well two days prior to infection and 
transfected with siRNA 24 hours prior to infection with vSC56. 
β-galactosidase entry assay validation. 
As described previously, β-gal standards were used to ensure that the assay was 
operating within a measurable linear range and VIG was used as a positive control for 
inhibition of vSC56 entry (24). Briefly, 7 standard concentrations of β-gal were serially 
diluted from a 1,500 U mL-1 stock solution (#10105031001, Roche Diagnostics, 
Indianapolis, IN) to 0.6, 1.2, 2.3, 4.7, 9.4, 18.6, and 37.5 mU mL-1 in 4:1 Z-buffer:PBS. 
The series of β-gal standards was then incubated with AgNPs at 4, 8, 16, 32, 64, 128, 
256, 512, and 1024 μg mL-1 for 1 hour at 37°C. After one hour 20 μL of a 4 mg mL-1 
chlorophenol red β-D-galactopyranoside (CPRG) substrate (#10884308001, Roche 
Diagnostics, Indianapolis, IN) in 0.1 M sodium phosphate (pH = 7.0) was added to each 
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standard and incubated at room temperature for 30 minutes. At 30 minutes the OD at 570 
nm was read as described in the previous section. The OD values were normalized to 
AgNP only wells to account for any OD readings brought about by the AgNPs 
themselves. The standard/AgNP OD values were then plotted against the β-gal 
concentrations to generate an XY scatter plot from which a linear trend line could be 
established. The linear trend line was then subjected to R2 analysis (Microsoft Excel 
2003, Microsoft Inc., Redmond, WA). R2 values less than 0.99 were considered 
unacceptable, as the standard enzyme did not catalyze the substrate properly. β-gal 
standards were run in parallel for each β-gal assay to determine if the results were in the 
linear range and acceptable. VIG was used as a positive control to determine if the assay 
was capable of detecting vSC56 entry inhibition. The VIG was serially diluted 2-fold and 
incubated with vSC56 at an MOI of 10 for 1 hour at 37°C. After the one-hour incubation 
the infections with the VIG/vSC56 mixture were carried out and ODs collected as 
detailed in the previous section. 
Confocal microscopy entry assay with fluorescent VACV.  
Vero 76 cells were plated onto glass cover slips in the bottom of 6-well plates 24 
hours prior to infection at 5 x 105 cells per well. Fluorescent virus WR-A4-GFP was then 
diluted to an MOI of 1,000 in complete medium containing various concentrations of 
AgNPs and incubated for 1 hour at 37°C. The AgNP/WR-A4-GFP mixture was then 
added to cells after the 1-hour incubation for the virucidal condition. For the 
cytoprotective condition, cells were incubated with various concentrations of AgNPs in 
complete medium for 1 hour prior to aspiration and addition of untreated WR-A4-GFP at 
an MOI of 1,000 in complete growth medium. Infections for both the virucidal and 
 
87 
cytoprotective conditions were carried out for 1 hour at 37°C when each well was 
aspirated. A solution of 1 μM CellTracker Red CMPTX (C34552, Invitrogen, Carlsbad, 
CA) in serum free medium was then added to each well and incubated at 37°C for 20 
minutes. After 20 minutes the CellTracker solution was removed via aspiration and the 
cover slips were washed with PBS twice. The cover slips were then fixed with 3.7% 
formaldehyde in PBS for 30 minutes. Cover slips were then removed from their 
respective wells and mounted on glass microscope slides for viewing on an Olympus FV-
300 confocal microscope equipped with both 488 and 568 nm argon and krypton laser 
excitation lines, respectively. Scans were acquired every 0.4 μm starting below the 
monolayer and proceeding past the top of the monolayer to encompass each cell in the 
viewing area. Green and red channels were acquired separately then merged via Fluoview 
5.0 software. Each z-stack was then analyzed frame by frame with Image-Pro 6.2 
software (Media Cybernetics, Inc., Bethesda, MD) to manually tag each green core 
within the cytoplasm, stained red by CellTracker Red CMPTX. A total of n = 3 
experiments were conducted for each condition and for each experiment a minimum of 
150 cells were counted for each condition. Core counts were normalized to the number of 
cells per condition per experiment. Percentages of untreated controls were then calculated 
for each experiment and averaged together. For confocal entry assays involving the 
knockdown of Pak1, cells were plated 48 hours prior to infection.  At 24 hours prior to 
infection the cells were transfected with siRNA specific for Pak1. 
Pak1 knockdown via siRNA.  
The knockdown of Pak1 was accomplished by transfecting 50 pmol of each of 
three separate 27-mer siRNAs with Lipofectamine 2000 (Invitrogren) per 5 x105 cells, 24 
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hours prior to use in experiments, according to manufacturers protocols. The siRNA was 
designed to target regions of high homology for Pak1 between Homo sapiens (NCBI 
Gene ID # 5058), Mus musculus (NCBI Gene ID # 18479, Macaca mulatta (NCBI Gene 
ID # 698585) and Callithrix jacchus (NCBI Gene ID # 100392970). The target sequence 
of siRNA1 is UUAGCUUGACAGAGCCAUCCAUUCCCA. The target sequence of 
siRNA2 is AGUCUCAGACACAGCCUUCACAUUCAA. The target sequence of 
siRNA3 is AUUAUAAUCCUCAGCUGACUUAUCUGU. All siRNAs were synthesized 
by Integrated DNA Technologies (IDT, Coralville, IA). 
Western blotting. 
Cellular lysates were created by pelleting cells at 0.3 x g after trypsinization then 
adding lysis buffer containing phoshatase inhibitors (50 mM Tris-HCl pH 8, 120 mM 
NaCl, 5 mM NaPPi, 10 mM NaF, 30 mM paranitrophenylphosphate, 1 mM benzamidine, 
0.1%NP-40, 1% Triton X-100, and 0.2 mM PMSF, 100 nM sodium orthovanadate) 
supplemented with protease inhibitors. A BCA protein content analysis kit was then used 
to determine the protein content of the lysates (#23221, Thermo-Fisher-Peirce, 
Pittsburgh, PA). Fifty micrograms of protein were then diluted and boiled for 10 minutes 
with a loading dye containing 0.5M dithiothreitol, 10% sodium dodecyl sulfate, 0.5M 
Tris (pH 6.8), 50% glycerol and 0.2% bromophenol blue. Lysates were then resolved on a 
10 % SDS-PAGE gel (C = 3.3%) and then transferred to a polyvinylidene fluoride 
membrane (PVDF). The PVDF membrane was then probed with primary antibody 
specific for Pak1, β-actin, G9 or GFP according to manufacturer specifications. 
Secondary antibody conjugated to horseradish peroxidase were then added according to 
manufacturer protocol then detected via Supersignal Westpico Chemiluminescent 
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Substrate kit (Thermo-Fisher-Pierce, Pittsburg, PA). Chemiluminesense was detected 
using a Fuji LAS-4000 gel documentation center (Fujifilm, Tokyo, Japan). Densiometry 
readings were measured via Multiguage software (Fujifilm). For the western blot 
analyzing mobility shift in G9 and A4-GFP, AgNPs were added directly to WR-A4-GFP 
stocks at 0, 10, 100, or 1,000 ug mL-1, then incubated for 1 hour at 37°C for one hour. 
After one hour, virus was lysed by adding 2x radio-immuno-precipitation-assay (RIPA) 
buffer to an equal volume of virus/AgNP mixture and the whole lystae was then resolved 
by SDS-PAGE and immunoblot analysis, as described above. The 2x RIPA buffer 
contained 300 mM sodium chloride, 2% IGEPAL CA-630, 1% sodium deoxycholate, 
0.2% SDS and 100 mM Tris, pH = 8.0.  
Plaque reduction assays.  
Plaque reduction assays were conducted using WR-A4-GFP tittered at 8.6 x109 
pfu mL-1 as the untreated control. For the cytoprotective condition of the plaque reduction 
assays, cells were incubated with various concentrations of AgNPs (one concentration per 
experiment) for 1 hour at 37°C prior to infection with 10-fold serial dilutions of untreated 
virus in complete growth medium. Virucidal plaque reduction assays were conducted by 
incubating the 10-fold serial dilutions of WR-A4-GFP with concentrations of AgNPs at 
32 μg mL-1 for one hour at 37°C prior to infecting BS-C-1 monolayers. This 
concentration of AgNPs was used for the plaque assays as it demonstrated significant 
inhibition of viral entry during the β-gal for overall VACV entry. After the hour 
incubation of the cells with AgNPs for the cytoprotective condition or the virus with 
AgNPs for the virucidal condition infections were performed in a procedure identical to 
that detailed in the “Viral titering” section. For post-infection plaque reduction assays 
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infections were carried out as described in the “Viral titering” section with the addition of 
AgNPs at 32 μg mL-1 to the 1.25 % SeaPlaque agarose overlay. 
Cytotoxicity of AgNPs.  
Vero 76 cells were plated at 2.5 x105 cells per well in 96-well plates 24 hours 
prior to treatment with AgNPs. On the day of each experiment AgNPs were diluted in 
complete growth medium and added to corresponding wells of the plate for 1, 4, 24 and 
48 hours. At the end of each time point the wells of the plate were aspirated and washed 3 
times with PBS then 100 μL of complete growth medium was again added to each plate 
along with 30 μL of a 1.66 mg mL-1 solution of MTT. The plate was then incubated for 4 
hours at 37°C. At the end of the 4 hours, cells and MTT were solubilized with 0.04 N 
HCl in 2-propanol at which point the OD at 570 nm was then read on a Dynex MRXe 
plate reader. Control conditions containing AgNPs and cells with no MTT were used to 
normalize the OD results for each AgNP condition and thus account for any OD reading 
from the AgNPs themselves.  
Statistical analysis, plots and IC50/LD50 Calculations.  
SigmaPlot 11.0 software (Systat & Mystat Products, Chicago, IL) was used to 
create graphs and conduct One-way ANOVA statistical alalyses. Percent of control 
values for test conditions were compared to the 100 % untreated control groups. P-values 
of less than 0.05 were considered statistically significant. Inhibitory concentration 50% 
(IC50) and lethal dose 50% (LD50) values were calculated according to the Karber Method 
with a positive or negative reaction boundary at 50 % of the untreated control (18). 





Effect of AgNPs on adsorption of VACV to host cells.  
In order to determine the point at which AgNPs inhibit VACV infection, 
adsorption of VACV was first investigated. The plaque assay used to measure adsorption 
of VACV relies on infecting cells at non-entry conditions, washing out unbound virions 
and then lysing cells to recover infectious virus that had adsorbed. AgNPs at 2, 8, 32, and 
128 μg mL-1 exhibited the same titer as the untreated condition, 0 μg mL-1 (Figure 1A). 
The slight increase in viral titers observed from VACV treated with 128 μg mL-1 was not 
statistically significant by One-way ANOVA analysis. The results of the plaque assay 
suggest that AgNPs at all concentrations tested had no effect on the adsorption of VACV 
to host cells. Confocal microscopy using a Western Reserve strain of VACV expressing 
GFP fused to the core protein A4 was then used to corroborate the findings of the plaque 
assay (Figure 1B). The confocal assay demonstrated that AgNPs at concentrations of 8, 
32, and 128 μg mL-1 had measurements within the range of the untreated control. Each of 
the concentrations tested was not statistically significant from the untreated control, as 
determined by One-way ANOVA. These results suggest that AgNPs had no affect on 




Figure 1. Effect of AgNPs on adsorption of VACV to host cells. A) Viral titers obtained from WR-A4-
GFP treated with various concentrations of AgNPs then allowed to adsorb to host cells under non-entry 
permissive conditions. B) Confocal microscopy quantification of WR-A4-GFP bound to host cells under 
non-entry permissive conditions after treatment with various AgNP concentrations. Each AgNP 
concentration is compared to the untreated control. 
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Effects of AgNPs on overall VACV entry.  
After adsorption, entry/fusion with the host cell is the next step in the VACV 
infection cycle. To monitor the effect of AgNPs on this stage of VACV infection, an 
assay measuring entry/fusion was developed utilizing VACV expressing β-gal under the 
control of a constitutively active promoter. Since the proposed assay utilized β-gal, the 
effect of AgNPs on the enzyme’s ability to catalyze its substrate was investigated. The R2 
values obtained from every AgNP treatment condition, from 2 through 1024 ug mL-1, 
were above the acceptability threshold of the assay indicating that the β-galactosidase 
enzyme activity is not altered by the presence of AgNPs (R2 > 0.99, data not shown).  
To further validate the β-gal assay as capable of measuring VACV entry at 4 
hours post-infection, a known inhibitor of entry, VIG, was used as a positive control. A 
clear dose dependent decrease in β-gal expression was found, with statistically significant 
inhibition starting at 48 μg mL-1, as determined by One-way ANOVA (p = 0.032, Figure 
2). Uninfected cells were used as a negative control and demonstrated OD values outside 
of the linear range of the assay indicating that the target cell line does not endogenously 





Figure 2. Validation of β-galactosidase VACV entry assay. β-galactosidase expression quantifying 
vSC56 entry in the presence of a known entry inhibitor, VIG. Each VIG concentration is compared to the 
untreated control. Asterisks above a data point indicate statistical significance, as compared to untreated 




Figure 3. Effects of AgNPs on overall VACV entry. Asterisks above a data point indicate statistical 
significance, as compared to untreated control for each treatment condition, according to One-way 
ANOVA (p ≤ 0.05, n = 3 for all experiments).  A) β-galactosidase expression from vSC56 quantifying 
overall viral entry in the presence of various NovaCentrix AgNP concentrations. The cytoprotective group 
represents cells incubated for 1 hour with AgNPs prior to infection with untreated vSC56. The virucidal 
group represents vSC56 treated with AgNPs for 1 hour prior to use in infection. Each AgNP condition is 
compared to the untreated control. B) Confocal microscopy quantification of WR-A4-GFP entry in the 
presence of various AgNP concentrations. The cytoprotective group represents cells incubated for 1 hour 
with AgNPs prior to infection with untreated vSC56. The virucidal group represents vSC56 treated with 




Figure 4. Tangential flow ultrafiltered AgNP virucidal effects on VACV entry. Asterisks above a data 
point indicate statistical significance, as compared to the untreated control, according to One-way ANOVA 
(p ≤ 0.05, n = 3). β-galactosidase expression from vSC56 quantifying overall viral entry in the presence of 
various filtered AgNP concentrations. 
 
Having established that VACV entry, and inhibition of this process, could be 
reliably detected, AgNPs were then evaluated for their potential virucidal and 
cytoprotective effects on overall VACV entry, both direct fusion and macropinocytosis-
dependent fusion. The cytoprotective condition, in which cells were incubated with 
AgNPs prior to infection with untreated virus, demonstrated statistically significant 
inhibition of viral entry, as determined by One-way ANOVA, starting at 8 μg mL-1, p = 
0.020, with a break in statistical significance at 16 μg mL-1, p = 0.107. Statistically 
significant inhibition resumed at 32 μg mL-1(p <0.001), and continued through the 
highest dose examined, 256 μg mL-1 (Figure 3A). Additionally, the cytoprotective 
condition exhibited a dose dependent decrease in VACV entry through the highest dose 
examined with an IC50 of 90.66 μg mL-1. The virucidal condition, in which VACV was 
treated with AgNPs prior to infection, exhibited statistically significant inhibition of 
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VACV entry, as determined by One-way ANOVA, starting at 32 μg mL-1, p = 0.003, and 
continuing through the highest dose tested, 256 μg mL-1. A dose dependent decrease in 
viral entry was also observed for the virucidal condition with a sharp drop in viral entry 
occurring above 32 μg mL-1. The IC50 value for the virucidal condition was 48 μg mL-1.  
Confocal microscopy was used to corroborate the findings of the β-gal entry assay 
using WR-A4-GFP. The cytoprotective condition exhibited a dose dependent decrease in 
VACV entry with statistically significant inhibition at 128 μg mL-1, p < 0.001 (Figure 
3B). The IC50 for the cytoprotective condition was 88 μg mL-1. The virucidal condition 
exhibited statistically significant and dose dependent inhibition of VACV entry starting at 
32 μg mL-1, with p = 0.010, and p = 0.001 for 32, and 128 μg mL-1 respectively (Figure 
3B). The IC50 value for the virucidal condition was 88 μg mL-1. Together, these data 
indicate that the β-gal entry assay can measure VACV entry and that AgNPs inhibit 
overall VACV entry at low, therapeutic level concentrations. 
Tangential flow ultrafiltered AgNPs were also used in the β-gal entry assay in a 
virucidal capacity (Figure 4). Much like the NovaCentrix AgNP examined in Figure 3, 
the filtered AgNPs exhibited a dose depended decrease in β-gal expression correlating to 
a decrease in vial entry. Statistically significant inhibition of VACV entry, as determined 
by One-way ANOVA, started at 16 μg mL-1 and continued through the highest dose 
tested (p = 0.015, n = 3). The IC50 value from the filtered AgNPs was 128 μg mL-1. The 
observation that two entirely different sets of AgNPs mediate an antiviral effects by 
preventing VACV entry suggests that AgNPs, in general, exert their antiviral effects at 




Effects of AgNPs on the direct fusion entry pathway of VACV after Pak1 
knockdown.  
In order to determine if the effect of AgNP inhibition of viral entry was specific to 
the direct fusion or macropinocytotic entry pathway of VACV, Pak1, a critical mediator 
of macropinocytosis by functioning as a key signaling kinase to affect cytoskeleton 
rearrangement, was knocked down via siRNA (25). Figure 5A demonstrates the efficacy 
of each siRNA, individually and all together, to knockdown Pak1 expression. After 
normalization to β-actin, siRNA#1, siRNA#2, and siRNA#3 demonstrated a 9, 54, and 
81% knockdown of Pak1, respectively. However, all three siRNAs together (All, Figure 
5A) were capable of generating an 87% knockdown of Pak1 expression compared to the 
non-silencing control. A qualitative analysis through the uptake of a fluorescently labeled 
dextran was also performed and demonstrated that all three siRNAs together reduced 
fluid phase uptake among target cells (Supplemental Figure 1). 
By knocking down Pak1 and subsequently reducing macropinocytosis in target 
cells the macropinocytosis-dependent entry of VACV would be largely reduced. In 
conjunction with Pak1 knockdown the ability of AgNPs to inhibit the direct fusion entry 
pathway of VACV was then examined with the β-gal entry assay. Knockdown of Pak1 
significantly inhibited VACV virus entry as β-gal expression values averaged only ~60% 
of the non-silencing control (data not shown). The cytoprotective condition exhibited 
very little ability to inhibit the direct fusion entry pathway of VACV with no statistically 
significant inhibition of viral entry revealed after One-way ANOVA analysis. 
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Figure 5. Effect of AgNPs on the direct fusion entry pathway of VACV after Pak1 knockdown.  
Asterisks above a data point indicate statistical significance, as compared to the untreated control for each 
condition, according to One-way ANOVA (p ≤ 0.05, n = 3 for all experiments). A) Western blot 
quantification of Pak1 knockdown via siRNA.  NSC = non-silencing control; All = all three siRNAs 
together. B) β-galactosidase expression from vSC56 quantifying VACV entry after Pak1 knockdown in the 
presence of various AgNP concentrations. Each AgNP concentration is compared to the silenced, untreated 
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control on the y-axis. One-way ANOVA analysis for statistical significance was performed on each AgNP 
treatment group compared to the silenced, untreated control. C) Confocal microscopy quantification of 
WR-A4-GFP entry after Pak1 knockdown in the presence of various AgNP concentrations. Each AgNP 
concentration is compared to the silenced, untreated control. A One-way ANOVA  was performed on each 
AgNP treatment group compared to the silenced, untreated control. 
 
No IC50 value was obtained for the cytoprotective condition. The virucidal condition 
exhibited a decrease in VACV direct fusion entry; however, the AgNP effect on direct 
fusion of VACV was less potent than that found during examination of overall VACV 
entry. Statistically significant inhibition of VACV direct fusion was only observed at 256 
μg mL-1, p = 0.001 (Figure 5B). The visible decreases in viral entry observed at 64, 128 
and 256 μg mL-1 corresponded to 23, 26, and 57% reductions in direct VACV entry 
compared to the Pak1 silenced, untreated control. No IC50 value was reached for the 
virucidal condition. These data indicate that AgNP anti-entry activity may largely require 
host cell functions dependent on Pak1 activity, such as macropinocytosis. However, a 
slight dose dependent decrease in viral entry was still observed for VACV treated with 
AgNPs prior to infection suggesting that AgNPs might prevent direct fusion in a virucidal 
fashion.  
Confocal microscopy was again used to corroborate the results of the β-gal entry 
assay. Silencing Pak1 demonstrated a significant effect on the number of WR-A4-GFP 
cores found in the cytoplasm, with an average of ~60% of the non-silencing control (data 
not shown). The cytoprotective and virucidal conditions exhibited no statistically 
significant inhibition of the direct fusion entry pathway for VACV at any of the doses 
examined (Figure 5C).. No IC50 values were reached for either condition. These confocal 
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data obtained during the knockdown of macropinocytosis-dependent entry demonstrate 
that AgNPs may require the function of Pak1, and possibly macropinocytosis, for 
effective inhibition of VACV entry. 
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Supplemental Figure 1. Fluid Phase Uptake Before and After Pak1 Knockdown. Vero 76 cells were 
plated at a density of 5 x105 cells per glass cover slip and transfected at 24 hours with three siRNAs 
targeting Pak1 as outlined in the methods section. At 24 hours post-transfection cells were infected with 
WR-A4-GFP as described in the methods section, then pulsed for 10 minutes with a 1 mg mL-1 solution of 
Rhodamine B-isothiocyanate (RITC) labeled 10,000 molecular weight dextran (#R8881, Sigma-Aldrich, 
St. Louis, MO). Cells were then washed three times with PBS then fixed for 30 minutes in 3.7% 
formaldehyde in PBS. Confocal images were then acquired, under identical exposure conditions, as 
described in the methods section. Both images above are examples of one slice taken through the middle of 
the z-stack acquired during analysis. Arrow indicates fluid phase uptake of the RITC-labeled dextran along 
with WR-A4-GFP.    
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Effects of AgNPs on the entire replication cycle of VACV.  
To determine if the inhibition of VACV by AgNPs translated to global decreases 
in VACV replication, a plaque reduction assay was performed. An AgNP dose of 32 μg 
mL-1 was chosen to perform these plaque assays because this dose demonstrated 
significant antiviral activity in the overall entry β-gal assay (Figure 3). Untreated VACV 
generated an average control titer of 8.6 x 109 pfu mL-1 (Figure 6, Untreated, n = 2). The 
virucidal condition, representing virus treated with 32 μg mL-1 for one hour prior to use 
in infection, demonstrated a titer of 1.5 x 106 pfu mL-1, a 3.8-log reduction in viral titer 
when compared to the untreated control (Figure 6, Virucidal, n = 2). The cytoprotective 
condition, representing cells treated with 32 μg mL-1 for one hour prior to infection with 
untreated virus, generated a titer of 6.6 x 105 pfu mL-1, a 4.1-log reduction in viral titer 
when compared to the untreated control (Figure 6, Cytoprotective, n = 2). The post-
infection condition, representing untreated cells infected with untreated virus and then 
treated with 32 μg mL-1 AgNPs, exhibited a titer of 1.5 x 105 pfu mL-1, a 4.8-log 
reduction in titer compared to the untreated control (Figure 6, Post-Infection, n = 2). The 
virucidal, cytoprotective, and post-infection treatments of 32 μg mL-1 AgNPs 
demonstrated statistically significant differences from the untreated control as determined 
by One-way ANOVA, p = 0.009, p = 0.009, and 0.012 respectively. Additionally, a 2-log 
reduction in viral titer was observed at both 8 and 16 μg mL-1 of virucidal treatment with 
AgNPs (data not shown, n = 1 for both). The inhibition of the entire VACV replication 
cycle suggests that AgNP inhibition of VACV entry has profound effects on viral 
replication kinetics whether AgNPs are administered in cytoprotective, virucidal, or post 
 104 
infection fashion. Such drastic inhibition of viral replication could also be the result of an 
as yet unknown mechanism(s). 
 
Figure 6. Effects of AgNPs on the entire replication cycle of VACV. The Untreated group represents 
VACV receiving no AgNP treatement. The Virucidal group represents VACV treated with 32 μg mL-1 
AgNPs for 1 hour prior to infection. The Cytoprotective group represents cells treated with 32 μg mL-1 
AgNPs for 1 hour prior to infection. The Post-Infection group represents untreated cells infected with 
untreated VACV then overlaid with a 1.25 % agarose growth medium containing 32 μg mL-1 of AgNPs. 
Asterisks above a data point represent statistical significance, as compared to the untreated control, 
according to One-way Anova (p ≤ 0.05, n = 2 for all). 
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AgNPs bind to the entry fusion complex of VACV.  
Western blot was used to investigate the potential of AgNPs to bind to the EFC of 
VACV to establish a possible mechanism of AgNP-mediated antiviral activity. A 
reproducible (n = 2), dose dependent decrease in the mobility of EFC complex protein G9 
was observed upon treatment of whole VACV virions with AgNPs (Figure 7, top panel). 
Treatment of the virus at 100 and 1,000 μg mL-1 of AgNPs retarded the mobility of G9 
equally, with 10 μg mL-1 showing retardation between that of the untreated control and 
the bands at 100 and 1,000 μg mL-1. The untreated control showed a typical migration 
pattern of a ~39 kD protein, G9 = 38.7 kD. Since the WR-A4-GFP virus was used for 
these experiments, it was then possible to examine the migration of A4-GFP on the same 
blot to determine if AgNPs were capable of penetrating the viral membrane and binding 
the core fraction of the virus (Figure 7, bottom panel). The majority of the A4-GFP 
protein showed no mobility shift as indicated by the thicker bands in the lower panel of 
Figure 7; however, the 100 and 1,000 μg mL-1 AgNP treatment conditions had a small 
portion of the total A4-GFP protein demonstrating a mobility shift .The shift in A4-GFP 
was dose dependent with decreased mobility associated with increased AgNP dose. It is 
possible that the process of lysing the virions gave excess AgNPs in the solution a chance 
to bind the core proteins as well. These results suggest AgNPs are capable of binding to 
viral proteins. Since G9 is an integral member of VACV’s EFC this binding may hinder 





Figure 7. AgNPs bind to the entry fusion complex of VACV. WR-A4-GFP was treated with 0, 10, 100 
or 1,000 μg mL-1 AgNPs (indicated above the blots) and then subjected to western blot with antibodies 
specific for the G9 protein, a member of the EFC, or GFP to detect mobility shifts in the respective 
proteins. 
 
Cytotoxicity of AgNPs. 
In order to determine if the inhibition of viral entry was a function of AgNP 
cytotoxicity and to gauge the therapeutic index of AgNPs, a standard MTT 
metabolic/cytotoxicity assay was performed. At one hour of AgNP exposure, mimicking 
the cytoprotective condition of the β-gal assays and all the confocal data, no statistically 
significant cytotoxic effects were detected as determined by One-way ANOVA 
comparing each dose to the untreated control (Figure 8, 1 hr). No LD50 was reached at 1 
hour of AgNP exposure. At 4 hours of AgNP exposure, mimicking the virucidal 
condition of the β-gal assays, there was a dose dependent decrease in the metabolic 
function of the target cells starting at 32 μg mL-1 and continuing through the highest dose 
tested (Figure 8, 4 hr). Statistically significant metabolic decreases, attained through One-
way ANOVA comparing each dose to the untreated control, were observed above 64 ug 
mL-1, p < 0.001. However, the widely used trypan blue assay for detecting membrane 
integrity, demonstrated that at 4 hours of AgNP exposure cell membranes were intact 
excluding the dye. No differences in cellular morphology were detected at this 
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magnification for all AgNP concentrations tested in the MTT assay. These data indicate 
that at 4 hours of AgNP exposure the cells were intact but impaired metabolically 
(Supplemental Figure 2, dead cells associated with dye uptake indicated with arrows). At 
24 hours of AgNP exposure there was no statistically significant cytotoxicity, as 
determined by One-way ANOVA comparing each dose to the untreated control, 
indicating that the decreased metabolic function observed at 4 hours was a temporary 
state and that the cells recovered  (Figure 8, 24 hr).. A One-way ANOVA analysis of 
MTT results from cells exposed to AgNPs for 48 hours exhibited no statistically 
significant decrease in metabolic function when compared to the untreated control 
(Figure 8, 48 hr). These findings show that AgNPs exert their antiviral, anti-entry effects 
at non-cytotoxic concentrations and that there may be additional mechanism(s) for AgNP 





Figure 8. Cytotoxicity of AgNPs. MTT cytotoxicity data collected after 1, 4, 24 and 48 hours of exposure 
to various AgNP concentrations (time points indicated in the bottom left hand corner of each graph). The 
percent of control on the y-axis refers to the untreated control at each time point. Asterisks above a data 
point indicate statistical significance, as compared to the untreated control for each time point, according to 
One-way ANOVA (p ≤ 0.05, n = 3). 
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Supplemental Figure 2. Trypan Blue Exclusion Cytotoxicity Assay. Vero 76 cells were plated out at 2.5 
x 105 cells per well in a 96-well plate 24 hours prior to exposure to AgNPs. Cells were then exposed to 
AgNPs, at the doses listed in the top left corner of each panel, for 4 hours. Cells were washed once with 
PBS then 80 μL of growth medium and 20 μL of trypan blue 0.4% were added to each well. Pictures were 
taken on a Leica Ctr-6000 inverted microscope with the aide of Image Pro 6.2 software. Bar = 100 μm for 
all panels. Arrows indicate dead cells no longer excluding the trypan blue dye. 
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DISCUSSION 
AgNPs have been observed to inhibit the viral replication cycle; however, while 
the literature suggests an early time point in the viral replication process, little more is 
known. This study identifies a distinct step in the viral replication cycle at which AgNPs 
exert their antiviral effects. First, adsorption of VACV to host cells, the earliest in early 
VACV replication processes, was examined to determine if this step of infection was 
indeed the one interrupted by AgNPs to yield antiviral activity. No significant changes in 
VACV adsorption were found among any of the AgNPs concentrations tested suggesting 
that AgNPs do not interfere with the either the cellular proteins or VACV proteins 
responsible for binding to host cells (Figure 1). It could be that the large branched 
structure of the cellular factors heparan sulphate, chondroitin sulphate and laminin or 
their viral binding counterparts A26 A27, D8, H3, and L1 are unperturbed by the binding 
of AgNPs because this interaction is not dependent on a conformational change but rather 
an electrostatic interaction (15). The binding of AgNPs may not abolish this charge 
interaction or the AgNPs are capable of mimicking the charges responsible for normal 
virus/host interaction via their highly polarizable surfaces, thus re-establishing any 
abolished binding activity. 
After determining that AgNPs did not affect adsorption, an assay was successfully 
established to measure overall VACV entry, both direct fusion and macropinocytosis-
dependent fusion (Figure 2). This assay, based on the expression of β-gal driven from a 
constitutively active early/late promoter, demonstrated that the reporter enzyme was 
unaffected by the concentrations of AgNPs used in this study. Additionally, this assay 
was capable measuring decreased VACV in conjunction with a known VACV entry 
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inhibitor, VIG (Figure 2). These data demonstrated that VACV entry, or cores 
translocated into the cytoplasm which immediately begin to transcribe early viral mRNA 
resulting in early gene expression, can be accurately measured during a 4 hour, post-
infection entry window. Successful reporter-based assays for VACV entry have detailed 
the measurement of entry as late as 6 hours post infection further suggesting that reporter 
assay detailed here, at 4 hours, is well within the generally accepted time frame of VACV 
entry (16, 52). 
AgNPs were found to significantly inhibit the entry process of VACV during β-
gal entry assay at 4 hours and confocal microscopic investigation at 1 hour post-infection 
(Figure 3). The NovaCentrix AgNPs, a “top-down,” dry synthesis AgNP, had both a 
cytoprotective and virucidal effect on VACV measured by decreases in viral entry in both 
assays. Another set of AgNPs made via “bottom-up,” wet synthesis methods also 
demonstrated clear dose dependent virucidal effects on VACV entry (Figure 4). These 
findings agree with the literature suggesting that AgNPs exert antiviral steps at an early 
stage of viral infection and add to it by pinpointing the stage of viral infection, the 
entry/fusion process, at which AgNP antiviral activity occurs (12, 21, 23, 34, 41). These 
findings also suggest that inhibition of VACV by AgNPs may not be as dependent on 
AgNP size as HIV-1 has demonstrated (12). This size dependence was the result of the 
HIV-1 entry protein gp120 being spaced at predictable intervals on the virus. The lack of 
size dependence for VACV might indicate that the EFC responsible for VACV entry may 
not have such a regimented spacing on the outside of the virion or that the virion is 
simply too large for the ~11 nm filtered AgNPs and 25 nm NovaCentrix AgNPs to 
sterically hinder themselves when binding to viral entry proteins. 
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Since VACV is known to enter cells via two distinct mechanisms, direct fusion 
and macropinocytosis-dependent fusion, Pak1 siRNA was used to inhibit 
macropinocytosis and permit investigation of the AgNP effect on the direct fusion entry 
pathway of VACV (Figure 5). Pak1 was successfully knocked down to levels similar to 
those found previously in the literature to inhibit macropinocytosis (Supplemental Figure 
1) (25). Under these conditions, cytoprotective treatment with AgNP had almost no effect 
on VACV entry. These results might be explained by the AgNPs being too spaced out on 
the cell, at the lower concentrations, to bind to VACV or that they were exhausted by 
binding to cellular proteins before a chance interaction with VACV. Effective AgNP 
cytoprotective treatment of cells might indeed require macropinocytosis to bring AgNPs 
and VACV into closer proximity in order to facilitate an inhibition of entry as AgNP 
uptake into cells is macropinocytosis-dependent (2, 14). For example, in the tubular 
domains of an endosome, which are between 50-90 nm in diameter, a 25 nm particle, 
such as those used in this study, could occupy up to half of the luminal space (26). In the 
vacuolar lumen of a macropinosome, which is between 200-1,000 nm in diameter, a 25 
nm AgNP would occupy 2.5-12.5% of that diameter while a VACV virion, between 250-
350 nm, would occupy 25-35% of the that diameter (9, 26). While these values are 
considering only two dimensions, the reduction in volume of the macropinosome as it 
matures would increase the likelihood of VACV encountering an AgNP (9, 26). After 
such an encounter with an AgNP and subsequent inhibition of fusion, the virus could 
become trapped within the endosome and destroyed in the lysosome (19). AgNPs used in 
a virucidal capacity were able to exert anti-entry effects on VACV’s direct fusion 
mechanism but at much larger doses than those observed during the overall entry assays. 
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The increasing doses required to inhibit entry may be a result of the incomplete inhibition 
of macropinocytosis and the excess AgNPs in the AgNP/VACV mixture creating 
cytoprotective effects. However, since the virucidal condition exhibited some anti-entry 
activity these results could also support the suggestion that AgNPs bind to the virus and 
inhibit infection at an early stage (12, 21, 23, 33).  
The entry inhibition results translated to a decrease in plaque formation, 
indicating that the AgNPs affected the overall replication cycle of VACV whether 
undergoing cytoprotective, virucidal or post-infection treatment with AgNPs (Figure 6). 
The decrease in post-infection titer as compared to the control could be due to preventing 
the spread of VACV after successful infection, as AgNPs were applied in the agarose 
overlay, or this inhibition could be the result of an as yet unknown mechanism. AgNP 
treatment did not cause increased viral titer, as assessed by plaque reduction assay, in any 
conditions tested as was previously described with a similar Orthopoxvirus, MPV (34).  
AgNPs were observed to decrease the mobility of G9 in a dose dependent fashion 
(Figure 7). G9 is one of the nine proteins of the EFC considered to be an integral member 
required for VACV entry. Furthermore, AgNPs altered the migration patter of the internal 
control core protein, A4-GFP. These data suggest that AgNPs bind to the viral proteins of 
VACV including the EFC. The shift observed in these experiments is small, ~ 1000 Da, 
but consistent with the findings that polyacrylamide gel pore sizes are between 21 nm, for 
gels with T = 10.5% and C = 5%, and 200 nm for gels with T = 4.6% and C =2 %, 
respectively (42). Since these experiments were conducted with T = 10% and C = 3.3%, 
values between those listed above, a 25 nm AgNP would likely pass through the pores, 
between 21 and 200 nm by the experimental conditions, and generate a small shift as seen 
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in Figure 7; however, precise pore sizes for these conditions are unknown. Additionally 
complicating issues related to G9 western blotting is the difficulty of solubilizing G9 and 
recovering enough protein to detect via western blot, which has been documented in the 
literature (28). This difficulty was overcome by increasing the detergents, reducing 
agents and time involved with lysate preparation; however, only low levels of the protein 
were detectable which results in lesser G9 blot image quality in Figure 6, (top panel vs. 
bottom). The observation that VACV direct fusion was mostly inhibited by virucidal 
AgNP treatment, and not cytoprotective treatment, in conjunction with the observations 
that AgNPs bind to G9, suggests that AgNPs could bind to VACV at the EFC and 
prevent viral entry. These observations support AgNP inactivation of viral entry proteins 
as one possible mechanism for AgNP antiviral activity. Additionally, these data are in 
agreement with previous findings in the literature demonstrating that AgNPs bind to the 
membrane bound proteins of viruses (12, 21). Alternatively, the shift in G9 could be a 
result of the stringent conditions used to solubilize the G9 protein. The literature provides 
no data concerning the fate of AgNPs subjected to the SDS-PAGE solubilization process, 
so phenomena brought about during such a procedure could also explain G9’s mobility 
shift. In future studies, extracting the proteins from the gel and running such assays as 
mass spectrometry might provide a better clue as to if G9 is bound by AgNPs. 
Cytotoxicity data suggest that AgNPs exert antiviral effects at non-toxic doses 
(Figure 8). While the MTT data support a decreased metabolic state at higher doses 
during a 4 hour exposure, microscopic evaluation, via the common and widely-used 
trypan blue staining assay for cell membrane integrity, revealed that cells at 4 hours of 
AgNP exposure excluded trypan blue. These results indicate that cellular membranes are 
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intact (Supplemental Figure 2). Furthermore, the observation that all conditions at 24 
hours of exposure to AgNPs were within the range of the untreated control suggest that 
the cells recovered from the decreased metabolic state observed at 4 hours; if the cells 
had been rendered non-viable by the AgNPs it is unlikely they would recover to the same 
cell numbers and combined metabolic state of the untreated control as detected by the 
MTT cytotoxicity assay at 24 hours. Since macropinocytosis is an active, energy-
dependent process, the decreased metabolic state may be creating a general antiviral-state 
for the target cell through the decrease in macropinocytosis brought on by decreased 
metabolic function within the cells (35). Further investigation into this possible 
mechanism of antiviral activity is warranted. Comparison of AgNPs used in this study 
with cytotoxicity data present in the literature is a difficult task due to the multitude of 
different AgNPs studied. Different AgNP characteristics such as size, shape, method of 
synthesis and capping/stabilizing agent can drastically alter the biological interaction of a 
nanomaterial (30, 47). Cytotoxicity values in the literature range from 0.7 μg mL-1 to 
greater than 449 μg mL-1 (1, 20). AgNPs used in this study were not toxic at antiviral 
concentrations suggesting they could be a potential therapeutic agent. 
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CONCLUSIONS 
This study examined two different sets of AgNPs and is the first of its kind to 
establish a precise stage in viral infection at which AgNP-mediated antiviral activity 
occurs. In addition to defining the stage at which AgNP antiviral activity occurs, the data 
presented here suggest a mechanism for the observed virucidal activity. This virucidal 
activity was observed in multiple species of virus in the literature and would suggest that 
any number of virus species as yet unstudied in the context of AgNP antiviral activity 
would be susceptible to inhibition. Additionally, observations made within this report 
suggest at least one additional mechanism of AgNP antiviral activity. This additional 
mechanism, seemingly linked to macropinocytosis and metabolism, may also be 
responsible for the antibacterial properties of AgNPs. The suggested alternative 
mechanism(s) would also have the potential to affect the infection process of many 
different viral species, as there are in fact many different species that use cellular uptake 
mechanisms to facilitate their infection processes. The fact that AgNPs can exhibit 
multiple methods of antiviral activity, at non-cytotoxic concentrations, makes them 
attractive as potential broad-spectrum antiviral therapeutics. 
AgNPs were capable of mediating a dramatic reduction in VACV entry at non-
cytotoxic concentrations. The reduction in viral entry was observed in both cytoprotective 
and virucidal capacity and was not due to the prevention of VACV adsorption to the host 
cell. Furthermore, AgNPs were successful at mitigating viral entry via the direct fusion 
and macropinocytosis-dependent entry pathways of VACV. The observations detailed 
within this report suggest at least two mechanisms by which AgNP-mediated antiviral 
activity occur. The virucidal aspect of AgNPs could be a result of the AgNPs binding to 
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proteins such as the G9 subunit of the EFC and preventing their normal function to 
facilitate viral entry or excess AgNPs in the AgNP/VACV infection mixture creating a 
decreased metabolic state and reducing either VACV early gene expression or preventing 
viral uptake via macropinocytosis. The AgNP cytoprotective observations demonstrate 
that there may be an additional mechanism(s) by which AgNPs prevent viral entry and 
infection. These additional mechanisms likely rely on a cellular response to AgNP 
treatment such as concentration of AgNPs within macropinosomes during the maturation 
process, decreased metabolism or a decrease in viral uptake via macropinocytosis 
creating a general antiviral-state.  
With the data collected here, in vivo studies of potential AgNP-mediated antiviral 
applications are possible and justified. Due to the multiple mechanisms at play AgNPs 
are uniquely suited for use as a stopgap treatment measure prior to identification of the 
infectious agent(s) in cases of anticipated or probable viral exposure. Currently, there are 
no truly broad-spectrum antiviral agents that can be used in such a manner. For airborne 
pathogens one might envision AgNPs administered via inhalation to prevent viral 
infection as they could offer virucidal effects for viruses that have not yet infected cells 
and cytoprotective effects for viruses that have not yet infected cells or are bound to 
airway tissues. There are currently no in vivo studies concerning AgNP antiviral activity 
and very few in vivo studies concerning AgNP toxicity. With the finding of these studies, 
such investigations are warranted. 
AgNPs have the benefit of multiple possible methods for delivery since they are a 
metal and resistant to changes in temperature and pressure unlike traditional antiviral 
drugs. Evidence collected here and in other literature sources also suggest that AgNPs 
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could mediate post exposure prophylaxis as well. AgNPs could also easily be used as a 
disinfectant for contact spread pathogens on delicate surfaces such as sensitive equipment 
and the skin. Furthermore, the use of AgNPs as a powder would be advantageous over 
traditional liquid decontaminants, such as bleach, in the clean up of sensitive equipment 
that would react poorly to liquid exposure. In each case the identity of the infectious 
agent need not be known due to the multiple mechanisms at play, which mediate AgNP 
antiviral activity and offer broad-spectrum antiviral activity. 
Future investigation into the mechanisms of AgNP antiviral activity is necessary. 
Additionally, in vivo investigation of potential AgNP antiviral applications is necessary. 
All together, these data suggest that AgNPs could be a potent broad-spectrum antiviral 
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CHAPTER V:  
DISCUSSION and CONCLUSION 
DISCUSSION 
Due to the exponential increase in biological applications for AgNPs, it is 
important that key gaps in knowledge surrounding their use are addressed. Chapter II of 
this dissertation sought to address the problems facing the manufacture of AgNPs for 
their use as antimicrobial agents without unwanted side effects common to contemporary 
AgNP synthesis and collection techniques. Developing a standard technology that is both 
high throughput and capable of simultaneously measuring AgNP antiviral activity and 
cytotoxicity is presented in Chapter III. A technology such as the one developed in 
Chapter III would greatly benefit the screening of nanomaterials for antiviral activity by 
enabling a automation of the process, standardizing the antiviral measurements and 
simultaneous assessing cytotoxicity. The fourth chapter addresses the unknown 
mechanisms involved in AgNP mediated antiviral activity by determining a stage at 
which antiviral activity occurs and suggesting possible antiviral mechanisms of action. 
Data presented here and in the literature suggest that AgNPs can be used as a new 
class of broad-spectrum antiviral agents. These antiviral agents would have numerous 
benefits over the traditional antiviral drugs and therapies. Since AgNPs are a metal there 
would be no limitations on storage conditions or restrictions in their method of 
application. Data presented here and in the literature concerning their ability to bind to 
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and inhibit a number of different viral species would suggest that they are a true broad-
spectrum antiviral, therefore in the instance of suspected viral exposure or at the onset of 
symptoms, a precise determination of the infectious agent is not necessary. Viral 
resistance to AgNPs would also be less prevalent than in traditional specific antiviral 
therapies due to the same non-specific biological interactions that grant AgNPs the ability 
to inhibit many different viral species. Despite all these potential benefits, many issues 
still surround the production of AgNPs, the screening of their antiviral potential against 
different viral species, and the determination of their precise time point and mechanism 
of antiviral activity. 
In order to produce highly concentrated, biocompatible AgNPs with low 
aggregation and narrow size distribution from a wet synthesis procedure, a tangential 
flow ultrafiltration procedure was constructed and tested against the common 
ultracentrifugation method for AgNP concentration. This procedure, which utilizes 
hollow fiber modules with specific pore sizes to solutes within a solvent, was capable of 
separating out a specific size population of naked AgNPs through upper and lower bound 
filters for AgNPs synthesized via the Creighton Colloid method. Wet synthesis methods 
of creating naked AgNPs, such as the Creighton method, produce a broad range of sizes, 
which can be problematic as different size AgNPs can cause different biological reactions 
(3, 10, 11). These differences are undesirable for the development of an antimicrobial 
agent as differentiating between harming the host or the target microbe is complicated 
due to the unknown effects caused by polydisperse AgNPs. The tangential flow 
ultrafiltration procedure concentrated AgNPs to a level 13-fold higher than the original 
colloid. This concentration effect is significant because the use of AgNPs as antiviral 
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agents relies on the number of AgNPs available to bind to a target microbe, a 
phenomenon less likely to occur in a less concentrated sample (24, 27, 37). Also, the 
ability to size select and concentrate AgNPs creates a highly uniform population of 
AgNPs that will increase antimicrobial efficacy and decrease unwanted side effects 
brought on by polydispersity.  
The tangential flow procedure for size selecting and concentrating AgNPs was 
then compared to the common AgNP harvesting method of ultracentrifugation. 
Tangential flow ultrafiltration was capable of concentrating AgNPs over 2.5-fold more 
than standard ultracentrifugation. The AgNPs collected via ultracentrifugation 
demonstrated a massive size distribution, high levels of aggregation and amorphous 
shapes when compared to the filtered AgNP. The large size distribution and introduction 
of various AgNP shapes would drastically affect normal biological processes which could 
generate cytotoxic effects that would be interpreted as antiviral activity (3, 4). Multiple 
reports detail the use of ultracentrifuged AgNPs for biological applications, such as the 
detection of cancerous versus non-cancerous cells, cytotoxicity studies, and general blood 
plasma screening for a variety of biomarkers (10). Any study employing 
ultracentrifugation to purify or concentrate nanoparticles may introduce errors into the 
data collected due to the different effects caused by a poly-disperse population of AgNPs, 
such as those generated by ultracentrifugation (11). By using AgNPs prepared by 
tangential flow ultrafiltration the likelihood of introducing errors based on AgNP poly-
dispersity is abrogated. This method ensures that any measured antiviral activity is due to 
the monodisperse, naked AgNPs themselves and not a function of contaminating 
synthesis agents, size polydispersity, or aggregation. 
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The findings of Chapter II indicate that tangential flow ultrafiltration is a 
preferable method to the traditional method of ultracentrifugation for concentrating 
AgNPs for use as antimicrobial agents. In addition to concentrating AgNPs, tangential 
flow filtration is capable of size selecting AgNPs to generate a uniform, mono-disperse 
population of AgNPs, while ultracentrifugation creates large aggregates and a large size 
distribution of AgNPs. The large size distribution of AgNPs produced by 
ultracentrifugation can introduce errors into data collected in the analysis of cytotoxicity 
and antimicrobial activity. These variations in AgNP characteristics from different 
synthesis techniques and concentration technique may cause other undocumented 
biological reactions that occur upon exposure to AgNPs. Thus, minimizing the risk of a 
diverse biological reaction from an AgNP population with broad size distribution is 
preferable when developing an antimicrobial agent. The use of ultrafiltration to 
concentrate other nanoparticles would provide a reliable, standardized method to reduce 
variability when testing the antimicrobial of any nanoparticles In addition to size 
selecting and concentrating AgNPs, this technique would work for any nanomaterial in 
liquid phase. Because of the greater control over the physical characteristics of 
nanomaterials, this filtering process will significantly advance the mobilization of 
nanotechnology into consumer and therapeutic products as antiviral and antibacterial 
agents. 
Chapter III presents a standard, high-throughput method of testing nanomaterials 
for antiviral activity to address the need for a standard antiviral screening method for 
nanomaterials. Because traditional plaque assays are subjective and require large amounts 
of time and money, a quicker high-throughput format for screening antiviral activity is 
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desirable. Additionally, current techniques rely on performing cytotoxicity assays 
separately from the antiviral testing. This separation can result in the masking of antiviral 
activity by cytotoxicity, as well as double the amount of work, time and money required. 
A large-scale HIV-1 mutation rate assay, based on colony forming units, was 
chosen as the basis for developing the new high-throughput antiviral assay. This assay 
utilized an HIV-1-based viral vector system that infects host cells and carries with it Hyg 
resistance so that only infected cells will be viable after addition of selective medium 
(14). The vector system was scaled down to a 96-well microtiter plate for ease of 
automation and high-throughput antiviral screening with an endpoint measurement by the 
standard MTT metabolic assay, a staple in the assessment of cell viability (6, 23, 25, 26). 
Because this new assay employs a viral vector system, the glycoproteins incorporated 
into the virion are interchangeable and thus multiple different viruses can be simulated 
and screened via the same standard assay simply by interchanging the target virus’s entry 
glycoprotein (8, 14). Standardization of antiviral screening was also established through 
the use of MTT as the endpoint measurement. Many labs are already equipped with the 
machinery and reagents required to conduct this assay and the National Cancer Institute’s 
Nanotechnology Characterization Laboratory lists MTT as one of only two standard 
methods for screening AgNP cytotoxicity (25, 35). Tetrazolium salts, such as MTT and 
its chemical relatives, have different wavelengths at which they absorb and thus can be 
interchanged to test different types of nanomaterials. This interchangeability is essential 
because different nanomaterials exhibit different SPR wavelengths that might interfere 
with the endpoint of the MTT (9, 19). By using different tetrazolium salts the assay 
remains the same standard assay from nanomaterial to nanomaterial and by using the 
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viral vector system the same standard assay can be used from virus to virus, affording a 
standardization and flexibility lacking in current methods. 
The new standard assay was then evaluated for its ability to accurately detect viral 
titers through comparison with the traditional colony forming unit assay. Changes in viral 
titers over three orders of magnitude were accurately measured by the new assay and 
confirmed via colony forming unit assay. These data indicate that the new high-
throughput assay is capable of detecting decreases in viral titer brought on by inhibition 
of infection. To the author’s knowledge this assay is the first example of a viral colony 
forming unit assay for antiviral activity in high-throughput, 96-well microtiter format.  
Once the new assay was established to accurately measure viral titer and thus 
inhibition of infection, AgNPs were used to gauge the assay’s ability to simultaneously 
measure antiviral activity and cytotoxicity. The new assay demonstrated that AgNPs 
clearly inhibited infection by the viral vector system. Furthermore, this antiviral activity 
was not accompanied by AgNP cytotoxicity. Traditional colony forming unit assays and 
reporter constructs are dependent on the living cells to gauge relative infectivity of a 
virus. If the antiviral agent being screened kills the target cells, a false positive for 
antiviral activity will be observed and interpreted as antiviral activity (36). The traditional 
assays must typically be run twice for each antiviral agent concentration tested in order to 
rule out possible toxicity; however, counting colonies can be a highly subjective process 
and thus introduces a large variation into the data collected (2, 20). Running the 
traditional assays in parallel to rule out possible cytotoxic effects add to the cost and time 
involved with each experiment thus preventing these technologies from achieving high-
throughput capabilities. Additionally, variations in cell number and MOI from assay to 
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assay will further cloud the distinctions between antiviral activity and cytotoxicity. This 
new assay eliminates the variations introduced in the traditional assays by permitting the 
simultaneous measurement of antiviral activity and cytotoxicity in the same plate. The 
viral vector system employed by this assay also permits a general indication of possible 
antiviral mechanisms at work by limiting the infection cycle to the point of proviral gene 
expression. Inhibition of the viral vector system can be interpreted as affecting the early 
processes during infection, an ability not present in the use of wild type virus colony 
forming unit assays which undergo all stages of viral replication. Inhibition of the viral 
vector system in this new assay indicates that antiviral activity occurs at early time points 
in infection and that AgNPs were observed to inhibit viral vector infection, this study is 
in agreement with current literature that indicate viral inhibition by AgNPs occurs at an 
early stage of viral infection (7, 17, 18, 29, 33, 34). 
In Chapter III a new high-throughput screening assay was successfully developed 
and found to simultaneously measure the antiviral activity and cytotoxicity of 
nanomaterials in a cell culture-based system. This assay represents a new system by 
which nanomaterials can be screened for antiviral activity in the absence of complications 
masking antiviral effects. Additionally, due to the parameters of this assay such as the use 
of MTT and interchangeable entry glycoproteins, this assay affords a level of 
standardization lacking in the assessment of nanomaterials as antivirals. The results of 
this assay can also serve as a “finger in the wind,” gauge from which the direction of 
future mechanistic studies of nanomaterial antiviral activity. In the process of validating 
this new assay with a contemporary nanomaterial, AgNPs showed clear antiviral effects 
and low cytotoxicity. These data demonstrate a potential antiviral agent with a high 
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therapeutic index. The AgNPs inhibited the virus at an early stage of replication prior to 
assembly of new particles in the cell. Further investigation into the mechanism of 
nanoparticle antiviral activity is warranted to determine if the AgNPs bind to the virus, 
the AgNPs bind to the cell, or both, are responsible for antiviral activity. 
The third objective of this manuscript, examined in Chapter IV of this manuscript, 
hypothesized that AgNP mediated antiviral activity was the result of AgNPs preventing 
viral entry. Two completely different sets of highly concentrated and uniform AgNPs 
were used in this objective to pinpoint the stage of viral infection at which AgNP 
antiviral activity occurs and illuminate possible mechanisms behind this inhibition, a vital 
gap in knowledge concerning AgNP antiviral activity. VACV was chosen as the viral 
system to examine AgNP-mediated antiviral activity and its possible mechanisms due to 
the call to research by various governmental agencies and the growing concern for the 
use of Variola major as a potential bioweapon. 
Adsorption of VACV to host cells was examined in the first aim of objective three 
to determine if AgNPs interrupted this process. AgNPs did not interfere with adsorption 
to the host cell, indicating that either the cellular proteins or the VACV proteins 
responsible for binding to host cells were unaffected by AgNPs. It is possible that the 
large branched structure of the cellular GAGs, or their viral binding counterparts, are 
unperturbed by the binding of AgNPs because this interaction is not dependent on a 
conformational change but rather an electrostatic interaction (13). The binding of AgNPs 
may not abolish this charge interaction or the AgNPs are capable of mimicking the 
charges responsible for normal virus/host interaction, thus re-establishing any abolished 
binding activity. 
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The effects of AgNPs on overall VACV entry, both direct fusion and 
macropinocytosis-dependent entry, were then investigated. Two distinct sets of AgNPs 
were found to significantly inhibit the entry process of VACV during β-gal entry assay at 
4 hours. Confocal microscopic investigation at 1 hour post-infection confirmed the 
findings of the β-gal entry assay. The AgNPs had both a cytoprotective and virucidal 
effect on VACV measured by decreases in viral entry in both assays. These findings are 
in agreement with the sources of literature that suggest AgNPs exert antiviral activity 
occurs during early stages of viral infection. This study expanded on the literature 
findings by pinpointing the precise stage of viral inhibition to the entry/fusion process (7, 
17, 18, 29, 34). Additionally, AgNPs were observed binding the G9 protein of VACV’s 
EFC through mobility shifts during Western blotting. The decrease in mobility supports 
previous observations of AgNPs binding to viral entry proteins as a mechanism for their 
virucidal activity (7). Inhibition of viral entry by AgNPs also translated to a decrease in 
plaque formation, indicating that the prevention of viral entry by AgNPs affected the 
overall replication cycle of VACV. This effect was observed whether undergoing 
cytoprotective, virucidal or post-infection treatment with AgNPs. Importantly, AgNP 
treatment did not cause increases in viral titer, as assessed by plaque assay, in any 
conditions tested as was previously described (29). 
Since VACV is known to enter cells via two distinct mechanisms, direct fusion and 
macropinocytosis-dependent fusion, the third aim of this objective used Pak1 siRNA to 
inhibit macropinocytosis and permit investigation into the AgNP affect on direct fusion 
of VACV to the target cell. Pak1 was successfully knocked down to levels similar to 
those found previously in the literature, at which macropinocytosis was inhibited (21). 
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Under these conditions, cytoprotective treatment with AgNPs had almost no effect, which 
indicates that inhibition of direct fusion of VACV by AgNPs might be prevented by the 
AgNPs being too spaced out on the cell at the lower concentrations to adequately prevent 
viral entry. Importantly, the cytoprotective effects of AgNPs might require 
macropinocytosis to bring AgNPs and VACV into closer proximity, thus facilitating a 
chance encounter and an inhibition of entry since AgNP uptake into cells is 
macropinocytosis-dependent (1, 12). In the tubular domains of an endosome, which are 
between 50-90 nm in diameter, a 25 nm particle, such as those used in this objective, 
could occupy up to half of the macropinosome’s luminal space (22). In the vacuolar 
lumen of a macropinosome, between 200-1,000 nm in diameter, a 25 nm AgNP would 
occupy 2.5-12.5% of that diameter while a VACV virion, averaging 250-350 nm in 
diameter, would occupy 25-35% of the that diameter (5, 22). While these values are 
considering only two dimensions, the reduction in volume of the macropinosome as it 
matures would increase the likelyhood of VACV encountering an AgNP. VACV could 
then become trapped within the endosome and destroyed in the lysosome as a result of a 
chance encounter with an AgNP during macropinosomal maturation (16). Supporting the 
suggestion that AgNPs bind to the virus and inhibit infection at an early stage, virucidal 
treatment of VACV elicited anti-entry effects on VACV’s direct fusion mechanism (7, 
17, 18, 28). 
These anti-entry effects by AgNPs were observed at non-cytotoxic concentrations of 
AgNPs as demonstrated by MTT assay and trypan blue exclusion indicating that AgNPs 
have a high therapeutic index. While the MTT assay showed decreased metabolic 
function at high AgNP doses for 4 hours of exposure, microscopic evaluation revealed 
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that cells at 4 hours of AgNP exposure were intact, excluding trypan blue. Combining the 
results from the MTT assay and trypan blue assay suggests that the cells are intact though 
experiencing a decreased metabolic state. Furthermore, the observation that all AgNP 
treatments at 24 hours of exposure were within the range of the untreated control suggest 
that the cells recovered from the observed decreased metabolic state at 4 hours. This 
recovery could be the result of the AgNPs binding to their maximum amount of 
biological material, thus creating the decline in metabolism. After the AgNPs have bound 
all the biological material possible including cellular and viral proteins, the cells may 
then regenerate the proteins inactivated by AgNP binding and thus accounting for the 
rebound in metabolic status. Since macropinocytosis is an active, energy-dependent 
process, the decreased metabolic state may also be creating a general antiviral-state for 
the target cell through the decrease in macropinocytosis brought on by decreased 
metabolic function within the cells (31). This decrease in metabolism and possible 
reduction in macropinocytosis preventing viral entry may be part of a mechanism 
responsible for the anti-entry effects of AgNPs. 
Chapter IV demonstrated that AgNPs inhibit VACV infection by preventing viral 
entry at non-cytotoxic concentrations. These effects were observed to occur at VACV 
entry in both a cytoprotective and virucidal capacity. Furthermore, observations were 
made that suggest multiple possible antiviral mechanisms of action. These possible 
mechanistic observations are significant as previous studies assessed viral systems 
covering more than one stage during viral infection or investigated the only the virucidal 
activity of AgNPs.  The results presented in this dissertation suggest AgNPs can be 
described as viral entry inhibitors. Additionally, by examining both the virucidal and 
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cytoprotective capacity of AgNPs, potent cytoprotective antiviral effects were observed 
in Chapter IV.  These cytoprotective effects could have even farther reaching potential as 
these effects most likely rely on active uptake by the host cells and could possibly be 
used to combat diseases associated with aberrant cellular uptake. These results lay down 
a framework upon which further investigation into the development of AgNPs as an 
antiviral agent and antiviral therapeutic is possible. Because AgNPs exhibited multiple 
mechanisms of action against VACV, which exploits multiple mechanisms for entry, 
AgNPs would be an ideal candidate as a new class of broad-spectrum antiviral agents. 
CONCLUSIONS 
 Nanotechnology’s presence is exponentially increasing in commercial 
applications. The applications of the most popular commercial nanotechnology AgNPs 
range from use as antiviral agents to cutting edge biosensors. However, this technology is 
still very young and requires better methods of generating AgNPs, better methods of 
studying their antiviral properties and a greater understanding of how AgNPs exert 
antiviral activity. The findings of these investigations suggest tangential flow 
ultrafiltration is capable of generating a highly uniform set of AgNPs. With this process 
more precise antimicrobial study is possible without the unwanted contaminants or 
adverse biological reactions possible when using AgNPs prepared via traditional 
methods. Additionally, other nanomaterials in the liquid phase can be concentrated and 
size selecting using this technique. These studies also proposed the use of a novel assay 
for screening nanomaterials for their antiviral potential. Tested with AgNPs, this assay 
exhibited the unique potential to measure cytotoxicity and antiviral activity 
simultaneously while enabling automation via its high-throughput format. AgNPs were 
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found to have low cytotoxicity and high antiviral activity indicating they have a high 
therapeutic index. This assay is also capable of screening other nanomaterials for 
antiviral activity and cytotoxicity simultaneously. AgNPs were found exert potent 
antiviral activity at non-cytotoxic concentrations with this new assay. Further 
investigation into the time point and mechanism of AgNP antiviral activity were also 
evaluated in these studies. AgNP antiviral activity was pinpointed to the entry stage of 
VACV infection where AgNPs were found to have both cytoprotective and virucidal 
effects at non-cytotoxic concentrations again suggesting that AgNPs have a high 
therapeutic index. This work also observed multiple mechanisms by which AgNPs may 
exert their antiviral properties. Because of the multiple methods of preventing viral entry, 
AgNPs would be ideal for further development as broad-spectrum antiviral agents. 
Future investigations into the antiviral activity of AgNPs can be divided up in the 
three basic categories. These categories are immediate investigations to take place within 
the next year, intermediate investigations to take place over the next five years, and long 
term investigations to take place over the next ten years. The first immediate 
investigation would concern the knockdown of Pak1 as discussed in Chapter IV. Because 
the siRNA system designed against Pak1 was only capable of an 87% knockdown, some 
Pak1 may be functional within the target cells. This unaffected Pak1 could then mediate a 
low level of macropinocytosis, thus allowing some of the VACV virions to enter the 
target cells via macropinocytosis-dependent fusion. A quantitative assay measuring 
macropinocytosis via fluid phase marker, such as a fluorescent dextran or horseradish 
peroxidase, would account for this possibility by generating a percent knockdown of 
macropinocytosis in conjunction with Pak1 knockdown. Characterizing the specific 
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decrease in macropinocytosis will enhance the data presented within this dissertation by 
providing a context for the level of VACV direct fusion inhibition by AgNPs. For 
example, if macropinocytosis is still occurs after Pak1 knockdown, a refined mechanism 
for AgNP antiviral activity would be apparent because the inhibition seen in Figure 4 
might be a result of AgNPs preventing fusion of virions contained within 
macropinocytotic vesicles. This refined mechanism would place more emphasis on the 
cytoprotective effect of AgNPs than on the virucidal potential of AgNPs. 
The effects of AgNPs on fluid phase uptake could be determined as part of the 
immediate investigations. Since a metabolic decline was observed at 4 hours of 
incubation with AgNPs above 64 μg mL-1, macropinocytosis could be decreased as well 
due to its dependence on the cell’s active metabolism. It would be vital to know if AgNPs 
could mediate such an effect for the development of an antiviral agent as well as a 
potential therapeutic for other diseases associated with aberrant macropinocytosis. 
Transmission electron microscopy examination of cellular morphology and membrane 
ultra-structure would also be useful in determining whether or not AgNPs are capable of 
preventing macropinocytosis. AgNPs limiting macropinocytosis would represent yet 
another mechanism by which AgNPs demonstrate antiviral activity. This antiviral activity 
would likely be broad-spectrum as a number of different viral species gain access to their 
target cells via macropinocytosis (22).   
The decrease in MTT values at 4 hours of AgNP exposure followed by a rebound 
to control levels at 24 hours of AgNP exposure suggests that AgNPs mediated a 
temporary decline in metabolism. A better understanding of the cytotoxic properties of 
AgNPs is required to understand if the decline in metabolism was beneficial to the cell by 
 142 
promoting a general antiviral state or if the decreased metabolism was due to damage 
associated with AgNP exposure. If the AgNPs can induce a decreased metabolic state 
from which the cells can recover, it would represent a novel form of broad-spectrum 
antiviral agent. This mechanism of antiviral activity would be affective against any 
possible viral pathogen due to the inhibition of early viral gene expression. Inhibition at 
this stage of viral infection could possibly deny the virus time to establish a foothold 
inside the cell and provide the immune system time react and effectively combat the 
intruder. To further explore the potential cytotoxicity of AgNPs an assay for apoptosis, an 
additional metabolic assay for viability and a necrosis assay could be used to determine 
how AgNPs may negatively impact the target cell. These data could be collected easily 
with an assay kit, such as ApoTox-Glo (Promega, # G6320, Madison, WI) containing all 
three assays performed in the same well. Other assays could provide support to the kit 
assay and build on its findings.  These additional assays could include a lactate 
dehydrogenase leakage assay to determine cellular necrosis, caspase activation assays to 
determine if AgNPs are causing apoptosis, ROS assays to determine if AgNPs are 
mediating ROS production, and ATP:ADP quantification assays to determine if 
mitochondrial function is impaired by AgNP exposure. Each of these assays could help to 
pinpoint possible negative impacts of host cell exposure to AgNPs as well as suggest if 
the AgNPs are capable of mediating an antiviral state due to decreased metabolism.  
In combination with the above assays for possible cytotoxic effects mediated by 
host cell exposure to AgNPs, a TEM analysis of AgNPs effects on cellular morphology 
could also be conducted in the immediate investigations. Such a study would detail when 
and where AgNPs were interacting with cells. For example, TEM could detect possible 
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increased AgNP concentrations in a macropinosome or where AgNPs bound to cellular 
membranes. By varying the time points at which samples were prepared for TEM a 
chronological analysis of when AgNPs collect at various organelles within the cell is 
possible. AgNP effects on cellular structure could also be determined and used to gauge 
possible cytotoxic effects as well.   
Based on the results generated by the quantitative macropinocytosis assay, 
cytotoxicity assays, and TEM analyses, intermediate investigations utilizing different 
target cells and viral strains would take place over the next five years. Different target 
cells could be selected for either increased or decreased basal levels of macropinocytosis. 
By studying viral entry in cell lines with varying levels of macropinocytosis a clearer 
understanding of how AgNPs exert their cytoprotective inhibition of VACV is possible. 
For example, in a cell line with higher levels of macropinocytosis, if VACV entry is 
inhibited to a greater degree after cytoprotective treatment with AgNPs, it would suggest 
that macropinocytosis is an active process required for AgNP-mediated anti-entry effects. 
Additional cell lines genetically designed without genes vital for macropinocytosis may 
also be a possibility for further examination of the mechanism behind AgNP effects on 
viral entry. Each of these scenarios would provide needed insight into the mechanism of 
AgNP-mediated inhibition of viral entry. These data would also shed light on possible 
methods of AgNP administration as an antiviral agent.  
Different viral VACV strains have demonstrated varying levels of dependence on 
macropinocytosis for entry into the host cell (5, 28). Using a strain that primarily 
accomplishes entry via direct fusion, one could more accurately determine the ability of 
AgNPs to prevent this method of viral entry. Conversely, strains that primarily utilize 
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macropinocytosis for entry into the host cell could be used to expand upon the research in 
this dissertation and further explore factors impacting AgNP inhibition of 
macropinocytosis dependent fusion such as AgNP dose, size, shape, and time of 
exposure. 
Examining other viral species’ susceptibility to AgNP-mediated inhibition of 
entry would also be beneficial for the intermediate investigation term. A particularly 
interesting virus system to examine AgNP antiviral activity would be the human 
pathogens of the Mastadenovirus genus, including the respiratory pathogens of Human 
adenovirus C. Unlike, the viruses in the literature that previously demonstrated 
susceptibility to AgNPs, Adenoviruses do not have a lipid membrane, or envelope. A 
result of Adenovirus inhibition would lend support to the broad-spectrum antiviral 
activity of AgNPs as well as be the first such study of nanotechnology to prevent 
Adenoviral infection. Other viral species could also be screened via the assay described 
in Chapter III. By inserting the glycoproteins of other viruses into the HIV-1 vector 
system a broad range of viral species could be simulated in a Biosafety-Level 2 
condition, such as biodefense threat viruses Lassa virus and Ebola virus, both of which 
have no approved antiviral treatment strategies. Each of these studies would also be the 
first of their kind to test a nanotechnology-based antiviral agent with each respective 
virus. 
Further exploration into the time point of AgNP exposure, with respect to the 
infection time point, and resulting antiviral effects is also warranted during the 
intermediate investigation. In Chapter IV, AgNPs added after infection were capable of 
inhibiting viral replication as measured by standard plaque assay. AgNPs could possibly 
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mediate other antiviral activities associated with the multiple stages of viral replication 
post entry. These replication effects could pertain to, but are not limited to, genetic 
replication, viral morphogenesis and viral exit from the host cell. Finding additional 
mechanisms of AgNP antiviral activity during these processes would justify continued 
development of AgNPs as a novel broad-spectrum antiviral agent. 
After examining AgNP antiviral activity in multiple viral species in vitro, 
significant data would exist to justify an in vivo approach to examining antiviral activity 
and cytotoxicity in the long term investigations. Very little data exist concerning AgNP 
toxicity in vivo. Generating a series of data concerning AgNP dose tolerance, delivery 
method, size effects and functionalization, such as targeting specific organs or increasing 
bioavailablity through surface modifications of the AgNPs, would be essential steps in 
exploring the potential use of AgNPs as antiviral agents. Additionally, there are no 
studies available concerning the antiviral potential of any nanotechnology in vivo. A 
mouse model would support a number of different viral infections and there are a 
numerous reagents designed specifically for such studies. Such a model would also be 
beneficial in determining the optimal method of AgNP delivery to prevent or treat viral 
infections.  
Due to the antiviral activity observed here and in the literature, AgNPs represent a 
novel class of broad-spectrum antiviral agents. AgNPs would have many benefits 
compared to other antiviral agents because they are a hearty metal and because of their 
broad-spectrum antiviral activity. Since AgNP antiviral activity occurred at non-cytotoxic 
concentrations, AgNPs would be further advantageous over current, toxic broad-spectrum 
antivirals. With the methods for the accurate production and screening of nanomaterials 
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also detailed within this manuscript, other nanoparticles can be quickly and accurately 
screened for antiviral activity. All together this work suggests that AgNPs, and 
potentially other nanomaterials, have a unique potential as a broad-spectrum antiviral 
agents and therapeutics. 
 147 
REFERENCES 
1. Asharani, P. V., M. P. Hande, and S. Valiyaveettil. 2009. Anti-proliferative activity 
of silver nanoparticles. BMC Cell Biol. 10:65. doi: 10.1186/1471-2121-10-65.  
2. Barber, P. R., B. Vojnovic, J. Kelly, C. R. Mayes, P. Boulton, M. Woodcock, and 
M. C. Joiner. 2001. Automated counting of mammalian cell colonies. Phys. Med. Biol. 
46:63-76.  
3. Bhattacharya, R., and P. Mukherjee. 2008. Biological properties of "naked" metal 
nanoparticles. Adv. Drug Deliv. Rev. 60:1289-1306. doi: 10.1016/j.addr.2008.03.013.  
4. Canamares, M. V., J. V. Garcia-Ramos, S. Sanchez-Cortes, M. Castillejo, and M. 
Oujja. 2008. Comparative SERS effectiveness of silver nanoparticles prepared by 
different methods: a study of the enhancement factor and the interfacial properties. J. 
Colloid Interface Sci. 326:103-109. doi: 10.1016/j.jcis.2008.06.052.  
5. Condit, R. C., N. Moussatche, and P. Traktman. 2006. In a nutshell: structure and 
assembly of the vaccinia virion. Adv. Virus Res. 66:31-124. doi: 10.1016/S0065-
3527(06)66002-8.  
6. DiStefano, D. J., S. L. Gould, S. Munshi, and D. K. Robinson. 1995. Titration of 
human-bovine rotavirus reassortants using a tetrazolium-based colorimetric end-point 
dilution assay. J. Virol. Methods. 55:199-208.  
 148 
7. Elechiguerra, J. L., J. L. Burt, J. R. Morones, A. Camacho-Bragado, X. Gao, H. 
H. Lara, and M. J. Yacaman. 2005. Interaction of silver nanoparticles with HIV-1. J. 
Nanobiotechnology. 3:6. doi: 10.1186/1477-3155-3-6.  
8. Escors, D., and K. Breckpot. 2010. Lentiviral vectors in gene therapy: their current 
status and future potential. Arch. Immunol. Ther. Exp. (Warsz). 58:107-119. doi: 
10.1007/s00005-010-0063-4.  
9. Evanoff, D. D.,Jr, and G. Chumanov. 2005. Synthesis and optical properties of silver 
nanoparticles and arrays. Chemphyschem. 6:1221-1231. doi: 10.1002/cphc.200500113.  
10. Feng, S., R. Chen, J. Lin, J. Pan, G. Chen, Y. Li, M. Cheng, Z. Huang, J. Chen, 
and H. Zeng. 2010. Nasopharyngeal cancer detection based on blood plasma surface-
enhanced Raman spectroscopy and multivariate analysis. Biosens. Bioelectron. 25:2414-
2419. doi: 10.1016/j.bios.2010.03.033.  
11. Gorth, D. J., D. M. Rand, and T. J. Webster. 2011. Silver nanoparticle toxicity in 
Drosophila: size does matter. Int. J. Nanomedicine. 6:343-350. doi: 10.2147/IJN.S16881.  
12. Greulich, C., J. Diendorf, T. Simon, G. Eggeler, M. Epple, and M. Koller. 2011. 
Uptake and intracellular distribution of silver nanoparticles in human mesenchymal stem 
cells. Acta Biomater. 7:347-354. doi: 10.1016/j.actbio.2010.08.003.  
13. Hsiao, J. C., C. S. Chung, and W. Chang. 1999. Vaccinia virus envelope D8L 
protein binds to cell surface chondroitin sulfate and mediates the adsorption of 
intracellular mature virions to cells. J. Virol. 73:8750-8761.  
 149 
14. Huang, K. J., and D. P. Wooley. 2005. A new cell-based assay for measuring the 
forward mutation rate of HIV-1. J. Virol. Methods. 124:95-104. doi: 
10.1016/j.jviromet.2004.11.010.  
15. Kahraman, M., O. Aydin, and M. Culha. 2009. Size effect of 3D aggregates 
assembled from silver nanoparticles on surface-enhanced Raman scattering. 
Chemphyschem. 10:537-542. doi: 10.1002/cphc.200800740.  
16. Kim, H. J., S. Lee, and J. U. Jung. 2010. When autophagy meets viruses: a double-
edged sword with functions in defense and offense. Semin. Immunopathol. 32:323-341. 
doi: 10.1007/s00281-010-0226-8.  
17. Lara, H. H., N. V. Ayala-Nunez, L. Ixtepan-Turrent, and C. Rodriguez-Padilla. 
2010. Mode of antiviral action of silver nanoparticles against HIV-1. J. 
Nanobiotechnology. 8:1. doi: 10.1186/1477-3155-8-1.  
18. Lu, L., R. W. Sun, R. Chen, C. K. Hui, C. M. Ho, J. M. Luk, G. K. Lau, and C. 
M. Che. 2008. Silver nanoparticles inhibit hepatitis B virus replication. Antivir Ther. 
13:253-262.  
19. Lu, X., M. Rycenga, S. E. Skrabalak, B. Wiley, and Y. Xia. 2009. Chemical 
synthesis of novel plasmonic nanoparticles. Annu. Rev. Phys. Chem. 60:167-192. doi: 
10.1146/annurev.physchem.040808.090434.  
20. MANSBERG, H. P. 1957. Automatic particle and bacterial colony counter. Science. 
126:823-827.  
 150 
21. Mercer, J., and A. Helenius. 2008. Vaccinia virus uses macropinocytosis and 
apoptotic mimicry to enter host cells. Science. 320:531-535. doi: 
10.1126/science.1155164.  
22. Mercer, J., M. Schelhaas, and A. Helenius. 2010. Virus entry by endocytosis. 
Annu. Rev. Biochem. 79:803-833. doi: 10.1146/annurev-biochem-060208-104626.  
23. Pabbruwe, M. B., K. Stewart, and J. B. Chaudhuri. 2005. A comparison of 
colorimetric and DNA quantification assays for the assessment of meniscal 
fibrochondrocyte proliferation in microcarrier culture. Biotechnol. Lett. 27:1451-1455. 
doi: 10.1007/s10529-005-1308-x.  
24. Pagba, C. V., S. M. Lane, H. Cho, and S. Wachsmann-Hogiu. 2010. Direct 
detection of aptamer-thrombin binding via surface-enhanced Raman spectroscopy. J. 
Biomed. Opt. 15:047006. doi: 10.1117/1.3465594.  
25. Pannecouque, C., D. Daelemans, and E. De Clercq. 2008. Tetrazolium-based 
colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. 
Nat. Protoc. 3:427-434. doi: 10.1038/nprot.2007.517.  
26. Patel, M. I., R. Tuckerman, and Q. Dong. 2005. A Pitfall of the 3-(4,5-
dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetra zolium 
(MTS) assay due to evaporation in wells on the edge of a 96 well plate. Biotechnol. Lett. 
27:805-808. doi: 10.1007/s10529-005-5803-x.  
 151 
27. Pavel, I., E. McCarney, A. Elkhaled, A. Morrill, K. Plaxco, and M. Moskovits. 
2008. Label-Free SERS Detection of Small Proteins Modified to Act as Bifunctional 
Linkers. J. Phys. Chem. C. Nanomater Interfaces. 112:4880-4883. doi: 
10.1021/jp710261y.  
28. Roberts, K. L., and G. L. Smith. 2008. Vaccinia virus morphogenesis and 
dissemination. Trends Microbiol. 16:472-479. doi: 10.1016/j.tim.2008.07.009.  
29. Rogers, J. V., C. V. Parkinson, Y. W. Choi, J. L. Speshock, and S. M. Hussain. 
2008. A Preliminary Assessment of Silver Nanoparticle Inhibition 
of Monkeypox Virus Plaque Formation. Nanoscale Res Lett. 3:129. doi: 10.1007/s11671-
008-9128-2.  
30. Rycenga, M., M. H. Kim, P. H. Camargo, C. Cobley, Z. Y. Li, and Y. Xia. 2009. 
Surface-enhanced Raman scattering: comparison of three different molecules on single-
crystal nanocubes and nanospheres of silver. J Phys Chem A. 113:3932-3939. doi: 
10.1021/jp8101817.  
31. Schelhaas, M. 2010. Come in and take your coat off - how host cells provide 
endocytosis for virus entry. Cell. Microbiol. 12:1378-1388. doi: 10.1111/j.1462-
5822.2010.01510.x; 10.1111/j.1462-5822.2010.01510.x.  
32. Shen, X. S., G. Z. Wang, X. Hong, and W. Zhu. 2009. Nanospheres of silver 
nanoparticles: agglomeration, surface morphology control and application as SERS 
substrates. Phys. Chem. Chem. Phys. 11:7450-7454. doi: 10.1039/b904712c.  
 152 
33. Sopova, E. A., V. I. Baranov, O. A. Gankovskaia, V. F. Lavrov, and V. V. 
Zverev. 2010. Effects of silver and silicon dioxide nanopowders on the development of 
herpesvirus infection in vitro. Gig. Sanit. (4):89-91.  
34. Speshock, J. L., R. C. Murdock, L. K. Braydich-Stolle, A. M. Schrand, and S. M. 
Hussain. 2010. Interaction of silver nanoparticles with Tacaribe virus. J. 
Nanobiotechnology. 8:19. doi: 10.1186/1477-3155-8-19.  
35. Stern, S. T., and T. M. Potter. 2006. Nanotechnology Characterization Laboratory, 
Method GTA-1 and GTA-2, Version 1.0. Nanotechnology Characterization Laboratory, 
National Cancer Institute. .  
36. Tonini, T., P. P. Claudio, A. Giordano, and G. Romano. 2004. Determination of 
functional viral titer by drug-resistance colony assay, expression of green fluorescent 
protein, and beta-galactoside staining. Methods Mol. Biol. 285:149-153. doi: 10.1385/1-
59259-822-6:149.  
37. Trefry, J. C., J. L. Monahan, K. M. Weaver, A. J. Meyerhoefer, M. M. 
Markopolous, Z. S. Arnold, D. P. Wooley, and I. E. Pavel. 2010. Size selection and 
concentration of silver nanoparticles by tangential flow ultrafiltration for SERS-based 
biosensors. J. Am. Chem. Soc. 132:10970-10972. doi: 10.1021/ja103809c.  
 
 
